

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

NIMENRIX®

Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine

Powder and diluent for solution for injection

Active Immunizing Agent

ATC Code J07AH08

Pfizer Canada ULC
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5

®GlaxoSmithKline Biologicals SA
Pfizer Canada ULC, Licensee

©Pfizer Canada ULC 2023

Date of Initial Authorization:
March 5, 2013

Date of Revision:
November 28, 2023

Submission Control Number: 273117

RECENT MAJOR LABEL CHANGES

4 DOSAGE AND ADMINISTRATION	05/2022
7 WARNINGS AND PRECAUTIONS	05/2022

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	4
4.1 Dosing Considerations	4
4.2 Recommended Dose and Dosage Adjustment	4
4.3 Reconstitution	5
4.4 Administration	6
5 OVERDOSAGE	6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	7
7 WARNINGS AND PRECAUTIONS	7
7.1 Special Populations	9
7.1.1 Pregnant Women	9
7.1.2 Breast-feeding	9
7.1.3 Pediatrics	9
7.1.4 Geriatrics	10
8 ADVERSE REACTIONS	10
8.1 Adverse Reaction Overview	10
8.2 Clinical Trial Adverse Reactions	10
8.5 Post-Market Adverse Reactions	16
9 DRUG INTERACTIONS	16

9.4	Drug-Drug Interactions	16
9.5	Drug-Food Interactions.....	17
9.6	Drug-Herb Interactions.....	17
9.7	Drug-Laboratory Test Interactions.....	17
10	CLINICAL PHARMACOLOGY	17
10.1	Mechanism of Action.....	17
11	STORAGE, STABILITY AND DISPOSAL	17
12	SPECIAL HANDLING INSTRUCTIONS.....	17
	PART II: SCIENTIFIC INFORMATION	18
13	PHARMACEUTICAL INFORMATION.....	18
14	CLINICAL TRIALS	18
14.1	Trial Design and Study Demographics	18
14.4	Immunogenicity.....	19
15	MICROBIOLOGY	39
16	NON-CLINICAL TOXICOLOGY	39
	PATIENT MEDICATION INFORMATION.....	40

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

NIMENRIX (meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine) is indicated for the active immunization of individuals from 6 weeks to 55 years of age against invasive meningococcal diseases caused by *Neisseria meningitidis* groups A, C, W-135 and Y.

1.1 Pediatrics

Pediatrics (≥ 6 weeks of age): The safety and efficacy of NIMENRIX in pediatric subjects 6 weeks of age and older have been established (see [4.2 Recommended Dose and Dose Adjustment](#), [8 ADVERSE REACTIONS](#) and [14 CLINICAL TRIALS](#)).

1.2 Geriatrics

Geriatrics (≥ 65 years of age): Limited safety and immunogenicity data are available in subjects 56 years of age and older (see [8 ADVERSE REACTIONS](#) and [14 CLINICAL TRIALS](#)).

2 CONTRAINDICATIONS

NIMENRIX should not be administered to subjects with known hypersensitivity to any component of the vaccine. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

NIMENRIX should be used in accordance with available official recommendations.

4.2 Recommended Dose and Dosage Adjustment

Age Group	Primary Immunization	Booster
Infants from 6 weeks to less than 6 months of age*	Two doses, each of 0.5 mL, with the first dose given from 6 weeks of age, and with an interval of 2 months between doses	At 12 months of age
Unvaccinated infants from 6 months to less than 12 months of age**	One dose of 0.5 mL given from 6 months of age	At 12 months of age with a minimum interval of at least 2 months after the primary dose
Children from 12 months of age, adolescents and adults**	One dose of 0.5 mL	Not routinely administered

* See [14.4 Immunogenicity: Immunogenicity in infants](#) for further information.

** In some situations, consideration may be given to administering an additional primary dose or a booster dose of NIMENRIX (see [7 WARNINGS AND PRECAUTIONS – Immune: Protection Against Meningococcal Disease](#) and [14 CLINICAL TRIALS](#) for further information).

Long-term antibody persistence data following vaccination with NIMENRIX are available up to 10 years after vaccination (see [7 WARNINGS AND PRECAUTIONS – Immune: Protection Against Meningococcal Disease](#) and [14 CLINICAL TRIALS](#)).

NIMENRIX may be given as a booster dose to individuals who have previously received primary vaccination with NIMENRIX or other conjugated or plain polysaccharide meningococcal vaccines (see [7 WARNINGS AND PRECAUTIONS – Immune: Protection Against Meningococcal Disease: Persistence of serum bactericidal antibody titres](#) and [14 CLINICAL TRIALS](#)).

4.3 Reconstitution

Parenteral Products:

In the absence of compatibility studies, NIMENRIX must not be mixed with other medicinal products.


Instructions for reconstitution of the vaccine with the diluent presented in pre-filled syringe

NIMENRIX must be reconstituted by adding the entire content of the pre-filled syringe of diluent to the vial containing the powder.


To attach the needle to the syringe, refer to the below drawing.

Note: However, the syringe provided with NIMENRIX might be slightly different (without screw thread) than the syringe described in the drawing. In that case, the needle should be attached without screwing.

1. Holding the syringe **barrel** in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.



2. To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock (see drawing).



3. Remove the needle protector, which on occasion can be a little stiff.

4. Add the diluent to the powder. After the addition of the diluent to the powder, the mixture should be well shaken until the powder is completely dissolved in the diluent.

After reconstitution, the vaccine should be used promptly. Although delay is not recommended, stability has been demonstrated for 8 hours at 30°C after reconstitution. If not used within 8 hours, do not administer the vaccine.

A new needle should be used to administer the vaccine.

4.4 Administration

NIMENRIX is for intramuscular injection only.

In infants, the recommended injection site is the anterolateral aspect of the thigh.

In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or deltoid muscle (see [7 WARNINGS AND PRECAUTIONS](#) and [9 DRUG INTERACTIONS](#)).

For instructions on reconstitution of the vaccine before administration, see [4.3 Reconstitution](#).

The reconstituted vaccine is a clear colourless solution.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

Any unused product or waste material should be disposed of in accordance with local requirements.

5 OVERDOSAGE

For management of a suspected vaccine overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

NIMENRIX is supplied as a sterile lyophilized white powder or cake in a single dose vial.

The diluent (sodium chloride and water for injections) is a sterile clear and colourless liquid supplied separately in a pre-filled syringe.

The vaccine does not contain any preservatives or adjuvants.

NIMENRIX is available as a single dose vial packaged with pre-filled syringe of diluent with or without needles in pack sizes of 1 and 10.

Table 1 Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form/Strength/Composition	Non-medical Ingredients
Intramuscular Injection	<p>Powder and diluent for solution for injection. After reconstitution, one 0.5 mL dose contains:</p> <p><i>Neisseria meningitidis</i> group A polysaccharide¹ 5 mcg</p> <p><i>Neisseria meningitidis</i> group C polysaccharide¹ 5 mcg</p> <p><i>Neisseria meningitidis</i> group W-135 polysaccharide¹ 5 mcg</p> <p><i>Neisseria meningitidis</i> group Y polysaccharide¹ 5 mcg</p> <p>¹ conjugated to tetanus toxoid carrier protein 44 mcg</p>	<p>After reconstitution, one 0.5 mL dose contains:</p> <ul style="list-style-type: none">• Sodium chloride 4.5 mg• Sucrose 28 mg• Trometamol 97 mcg• Water for injections q.s. to 0.5 mL

Traceability

To help ensure the traceability of vaccines for patient immunization record-keeping as well as safety monitoring, health professionals should record the time and date of administration, quantity of administered dose (if applicable), anatomical site and route of administration, brand name and generic name of the vaccine, the product lot number and expiry date.

7 WARNINGS AND PRECAUTIONS

General

NIMENRIX should under no circumstances be administered intravascularly, intradermally or subcutaneously.

It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.

Although NIMENRIX contains tetanus toxoid, this vaccine does not substitute for tetanus immunization.

Intercurrent Illness

As with other vaccines, vaccination with NIMENRIX should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Syncope

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

Hematologic

Thrombocytopenia and Coagulation Disorders

As with other vaccines administered intramuscularly, NIMENRIX should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.

Immune

Immunodeficiency

It may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate immune response may not be elicited.

Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* groups A, C, W-135 and Y even if they develop antibodies following vaccination with NIMENRIX.

Protection Against Meningococcal Disease

NIMENRIX will only confer protection against *Neisseria meningitidis* groups A, C, W-135 and Y. The vaccine will not protect against other *Neisseria meningitidis* groups.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

Immune response in infants aged 6 months to less than 12 months

A single dose administered at 6 months was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with three doses administered at 2, 4, and 6 months (see [14.4 Immunogenicity: Immunogenicity in infants](#)). The clinical relevance of this observation is unknown. If an infant aged 6 months to less than 12 months is expected to be at immediate risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second primary dose of NIMENRIX after an interval of 2 months.

Immune responses in toddlers aged 12-14 months

At 1 month post-vaccination, toddlers aged 12-14 months had similar rabbit complement serum bactericidal assay (rSBA) titres to groups A, C, W-135 and Y following one dose of NIMENRIX or two doses of NIMENRIX given 2 months apart. At one year post-vaccination, the percentage of subjects achieving rSBA titres $\geq 1:8$ for groups A, C, W-135 and Y were: 63.5%, 49.1%, 65.3% and 73.1% in the one dose group, and 70.6%, 55.2%, 77.6% and 79.7% in the two doses group (see [14.4 Immunogenicity: Immunogenicity in toddlers aged 12-23 months](#)).

One month post-vaccination, a single dose vaccination was associated with lower human complement serum bactericidal assay (hSBA) titres to groups W-135 and Y compared with two doses given 2 months apart, while responses to groups A and C were higher in the two groups. The clinical relevance of these observations is unknown. If a toddler is expected to be at particular risk of invasive meningococcal disease due to exposure to groups W-135 and/or Y, consideration may be given to administering a second primary dose after an interval of 2 months. At one year post-vaccination, the percentage of subjects achieving hSBA responses $\geq 1:8$ for groups A, C, W-135 and Y were 35.7%, 80.3%, 95.8% and 91.9% in the one dose group, and 35.5%, 90.5%, 98.5% and 87.9% in the two doses group. Regarding waning of antibody against group A or group C after a first dose of NIMENRIX in children aged 12-23 months, see [7 WARNINGS AND PRECAUTIONS - Persistence of serum bactericidal antibody titres](#).

Persistence of serum bactericidal antibody titres

Persistence of antibodies has been evaluated up to 10 years after vaccination. The persistence studies with NIMENRIX have shown a waning of serum bactericidal antibody titres against group A when using human complement in the assay (hSBA) (see [14.4 Immunogenicity](#)). The clinical relevance of this observation is unknown. However, if an individual is expected to be at particular risk of exposure to group A and received a dose of NIMENRIX more than approximately 1 year previously, consideration may be given to administering a booster dose.

Similar to the monovalent Men C comparator, a decline in antibody titres over time has been observed. The clinical relevance of this observation is unknown. A booster dose might be considered in individuals remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135 and Y (see [14.4 Immunogenicity](#)).

Reproductive Health: Female and Male Potential

See [7.1.1 Pregnant Women](#).

7.1 Special Populations

7.1.1 Pregnant Women

There is limited experience with use of NIMENRIX in pregnant women.

Animal studies with NIMENRIX do not indicate direct or indirect harmful effects with respect to fertility, pregnancy, embryo/fetal development, parturition or post-natal development (see [16 NON-CLINICAL TOXICOLOGY](#)).

NIMENRIX should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the fetus.

7.1.2 Breast-feeding

The safety of NIMENRIX when administered to breast-feeding women has not been evaluated. It is unknown whether NIMENRIX is excreted in human breast milk.

NIMENRIX should only be used during breast-feeding when the possible advantages outweigh the potential risks.

7.1.3 Pediatrics

Pediatrics (≥ 6 weeks of age): The safety and efficacy of NIMENRIX in pediatric subjects 6 weeks of age and older have been established.

7.1.4 Geriatrics

Geriatrics (≥ 65 years of age): Limited safety and immunogenicity data are available in subjects 56 years of age and older (see [8 ADVERSE REACTIONS](#) and [14 CLINICAL TRIALS](#)).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The safety profile is based on two data sets:

- A pooled analysis on 9,621 subjects who have been vaccinated with one dose of NIMENRIX in clinical studies. The pooled analysis includes data for 3,079 toddlers (12 months to 23 months), 1,899 children (2 to 10 years), 2,317 adolescents (11 to 17 years) and 2,326 adults (18 – 55 years). In addition, a descriptive study provides safety data from 274 individuals aged 56 years and older and who have been vaccinated with one dose of NIMENRIX.
- Data from approximately 1000 infants (6 weeks to 12 months of age) who have been primed and boosted with NIMENRIX.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials, therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Solicited Adverse Reactions

Infants 6 weeks to 12 months old

In Study MenACWY-TT-083, healthy infants received a primary series of two doses (at 2 and 4 months of age) of NIMENRIX or control vaccine (meningococcal group C CRM₁₉₇-conjugate vaccine [MenC-CRM] or meningococcal group C tetanus toxoid conjugate vaccine [MenC-TT]), with the first dose administered between 6 and 12 weeks of age, followed by a booster dose at 12 months of age. Routinely used infant vaccines DTaP/IPV/Hib/HepB and a 10-valent pneumococcal vaccine (PCV10) were coadministered. Table 2 presents the rates of solicited symptoms reported during the 4-day post-vaccination period.

Table 2 Study MenACWY-TT-083: Percentage of subjects with solicited local and general symptoms reported during the 4-day (Days 0-3) post-vaccination period (Primary and Booster Total Vaccinated cohorts)

	Type	NIMENRIX			MenC-CRM			MenC-TT		
		Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster
		N=523	N=516	N=510	N=509	N=507	N=496	N=517	N=508	N=503
Local Symptoms, %										
Pain	All	29.6	24.0	39.8	31.0	25.4	40.9	30.4	28.1	36.0
	Grade 3	3.3	2.1	4.5	2.4	1.8	6.3	4.6	2.4	3.6
Redness	All	24.5	32.6	43.3	27.1	42.2	42.9	27.1	38.8	45.3
	> 30 mm	0.2	0.0	1.2	0.4	0.0	1.0	0.2	0.2	0.8
Swelling	All	11.9	22.3	29.8	17.1	27.0	31.7	15.7	25.6	32.4
	> 30 mm	0.0	0.2	0.4	0.6	0.0	0.4	0.0	0.8	1.0
General Symptoms, %*										
	Type	NIMENRIX			MenC-CRM			MenC-TT		
		Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster	Dose 1	Dose 2	Booster
		N=523	N=516	N=510	N=508	N=505	N=496	N=517	N=507	N=504
Drowsiness	All	52.8	36.0	39.2	55.9	38.8	40.3	57.3	37.5	38.5
	Grade 3	4.2	1.4	1.8	3.1	2.2	3.6	6.2	2.6	2.6
Irritability	All	62.9	52.3	56.7	68.3	52.9	56.9	68.5	50.7	57.5
	Grade 3	7.6	5.4	6.3	7.7	6.3	7.1	9.7	7.5	7.7
Loss of appetite	All	38.4	33.1	36.3	37.4	29.7	38.1	41.4	29.6	37.3
	Grade 3	1.9	1.9	3.5	1.6	1.8	3.6	1.4	1.8	4.4
Fever (Rectally)	All ($\geq 38^{\circ}\text{C}$)	30.6	22.7	32.4	32.9	19.8	35.5	34.6	20.9	31.0
	$> 40^{\circ}\text{C}$	0	0.2	0.4	0	0.2	0.4	0	0.2	1.0

N= number of subjects with at least one documented dose. Doses 1 and 2 given at 2 and 4 months of age, respectively. Booster dose given at 12 months of age.

%= percentage of subjects reporting the symptom at least once

*Incidence of general symptoms reported for meningococcal vaccine (NIMENRIX, MenC-CRM or MenC-TT) coadministered with DTaP/IPV/Hib/HepB and PCV10

Toddlers 12 to 23 months old

In Study MenACWY-TT-039, healthy children 12 through 23 months of age were administered one dose of NIMENRIX either alone or co-administered with a first dose of PRIORIX-TETRA[®], 1 dose of PRIORIX-TETRA or 1 dose of a licensed MenC-CRM₁₉₇ (MenC-CRM) vaccine.

Table 3 presents the rates of solicited symptoms reported during the 4-day post-vaccination period in the Co-administered (Co-ad), NIMENRIX, PRIORIX-TETRA and MenC-CRM groups.

Table 3 Study MenACWY-TT-039: Percentage of subjects with solicited local and general symptoms reported during the 4-day (Days 0-3) post-vaccination period (Total vaccinated cohort)

	Type	NIMENRIX + PRIORIX-TETRA N=375	NIMENRIX N=367	PRIORIX-TETRA N=124	MenC-CRM N=123
Local Symptoms, %					
Pain	All	24.3	29.2	17.7	25.2
	Grade 3	0.3	0.8	0.0	0.0
Redness	All	35.5	37.1	38.7	31.7
	> 30 mm	1.9	4.4	0.0	0.0
Swelling	All	13.9	18.8	5.6	8.1
	> 30 mm	2.4	4.1	0.0	0.0
General Symptoms, %					
	Type	NIMENRIX + PRIORIX-TETRA N=375	NIMENRIX N=367	PRIORIX-TETRA N=124	MenC-CRM N=124
Drowsiness	All	32.5	28.1	23.4	32.3
	Grade 3	0.3	0.0	0.8	0.0
Fever (Rectally)	All ($\geq 38^{\circ}\text{C}$)	14.9	9.3	11.3	12.9
	>40°C	0.0	0.0	0.8	0.0
Irritability	All	50.7	40.9	38.7	43.5
	Grade 3	0.8	0.5	1.6	0.0
Loss of appetite	All	28.5	22.9	23.4	26.6
	Grade 3	0.3	0.0	0	0.0

N= number of subjects with the dose documented

%= percentage of subjects reporting the symptom at least once

Redness was the most frequently reported solicited local symptom in each group after each vaccination (38.7% in the PRIORIX-TETRA group, 35.5% in the Co-ad group, 37.1% in the NIMENRIX group and 31.7% in the MenC-CRM group).

Irritability was the most frequently reported solicited general symptom in the 4 groups (50.7% in the Co-ad group, 40.9% in the NIMENRIX group, 38.7% in the PRIORIX-TETRA group and 43.5% in the MenC-CRM group).

In Study MenACWY-TT-104, toddlers 12-14 months of age were vaccinated with either a single dose of NIMENRIX or two NIMENRIX doses administered 2 months apart. In the group who received two doses, the first and second doses were associated with similar local and systemic reactogenicity.

Children (2-10 years old), Adolescents (10-25 years old), and Adults (18-55 years old)

Children (2-5 years old)

In Study MenACWY-TT-081, healthy children 2 through 10 years of age were administered 1 dose of NIMENRIX or 1 dose of a licensed MenC-CRM vaccine.

Table 4 presents the percentage of subjects (2 through 5 years of age) with solicited adverse reactions during the 4-day post vaccination period in the NIMENRIX and MenC-CRM groups.

Table 4 MenACWY-TT-081: Percentage of subjects with solicited local and general symptoms reported during the 4-day (Days 0-3) post-vaccination period (Total vaccinated cohort), subjects 2 through 5 years of age

	Type	NIMENRIX N=162	MenC-CRM N=53
Local Symptoms, %			
Pain	All	27.8	28.3
	Grade 3	0.0	1.9
Redness	All	35.2	39.6
	>30 mm	6.8	15.1
Swelling	All	26.5	24.5
	>30 mm	4.3	5.7
General Symptoms, %			
Drowsiness	All	14.2	11.3
	Grade 3	0.0	1.9
Fever/(Orally)	All ($\geq 37.5^{\circ}\text{C}$)	5.6	5.7
	$>39.5^{\circ}\text{C}$	0.0	0.0
Irritability	All	15.4	11.3
	Grade 3	0.6	1.9
Loss of Appetite	All	10.5	9.4
	Grade 3	0.0	0.0

N= number of subjects with the dose documented

%= percentage of subjects reporting the symptom at least once

Redness was the most frequently reported solicited local symptom in each group (35.2% and 39.6% of the subjects in the NIMENRIX group and MenC-CRM group, respectively).

Irritability was the most frequently reported solicited general symptom in each group (15.4% and 11.3% of the subjects in the NIMENRIX group and MenC-CRM group, respectively). Drowsiness was also reported by 11.3% of the subjects in the MenC-CRM group, as compared to 14.2% of the subjects in the NIMENRIX group. Fever $\geq 37.5^{\circ}\text{C}$ was reported by 5.6% of the subjects in the NIMENRIX group and 5.7% of the subjects in the MenC-CRM. The majority of fevers were measured by the rectal route (66.7% in the NIMENRIX group and 100% in the MenC-CRM group).

Children (6-10 years old)

Table 5 includes the percentage of subjects (6 through 10 years of age) with solicited adverse reactions during the 4-day post vaccination period in the NIMENRIX and MenC-CRM groups.

Pain was the most frequently reported solicited local symptom in each group (43.9% and 54.0% of the subjects in the NIMENRIX group and MenC-CRM group, respectively). Fatigue was the most frequently reported solicited general symptom in each group (22.3% and 22.0% of the subjects in the NIMENRIX group and MenC-CRM group, respectively). Fever $\geq 37.5^{\circ}\text{C}$ was reported in 6.8% of the subjects in the NIMENRIX group and 2.0% of the subjects in the MenC-CRM group.

Adolescents (10-25 years old)

In Study MenACWY-TT-071, healthy subjects 10 through 25 years of age were administered 1 dose of NIMENRIX or 1 dose of MENACTRA[®] (ACWY-DT vaccine).

Table 5 includes the percentage of subjects (10 through 25 years of age) with solicited adverse reactions during the 4-day post vaccination period in the NIMENRIX and MENACTRA groups.

The most common solicited local symptom during the 4-day post-vaccination period was pain at the injection site, reported by 51.4% and 55.4% of subjects in the NIMENRIX and MENACTRA groups, respectively. A much smaller percentage of these subjects reported pain with grade 3 intensity, ranging between 0.6% and 2.4% across all vaccine groups.

The incidence of redness at the injection site was 25.8% and 20.3% of subjects in the NIMENRIX and MENACTRA groups, respectively. The incidence of swelling was 19.1% and 13.5% of subjects, respectively. The majority of these events were grade 1 in intensity. Grade 3 events of redness (i.e. > 50 mm in diameter) were reported by 3 and 6 subjects in the NIMENRIX and MENACTRA groups, respectively. Grade 3 events of swelling (i.e. > 50 mm in diameter) were reported by 3 subjects each of the two vaccine groups.

The most common solicited general symptom was fatigue with an incidence of 27.3% to 29.2% across the two vaccine groups. Headache was reported by 25.5% to 26.4% and gastrointestinal symptoms by 13.1% to 13.5% of subjects across the two vaccine groups.

Coadministration with other vaccines (Tdap and HPV2) has not been associated with increased local or systemic reactions in clinical studies.

Adults (18-55 years old)

In Study MenACWY-TT-035, healthy adults 18 through 55 years of age were administered either 1 dose of NIMENRIX, 1 dose of a licensed ACWY-PS (polysaccharide) vaccine, or 1 dose of NIMENRIX co-administered with a licensed influenza vaccine, FLUARIX®.

Table 5 includes the percentage of subjects (18 through 55 years of age) with solicited adverse reactions during the 4-day post vaccination period in the NIMENRIX, ACWY-PS and Co-administered groups.

Pain was the most frequently reported solicited local symptom in each group (19.4% in the NIMENRIX group, 21.9% in the Co-administered group and 13.5% in the ACWY-PS group). Headache was the most frequently reported solicited general symptom in each group (16.3% in the NIMENRIX group, 14.2% in the ACWY-PS group, and 13.3% in the Co-administered group).

Table 5 Percentage of subjects with solicited local and general symptoms reported during the 4-day (Days 0-3) post-vaccination period (Total vaccinated cohort), subjects 6 through 55 years of age

		MenACWY-TT-081		MenACWY-TT-071		MenACWY-TT- 035		
Age		6-10 Years old		10-25 Years old		18-55 Years old		
	Type	NIMENRIX N=148	MenC N=50	NIMENRIX N=329	MENACTRA N=325	NIMENRIX N=927	NIMENRIX + FLUARIX N=105	ACWY-PS N=310
Local Symptoms, %								
Pain	All	43.9	54.0	51.4	55.4	19.4	21.9	13.5
	Grade 3	2.0	6.0	2.4	0.6	0.4	1.0	0.3
Redness	All	39.2	38.0	25.8	20.3	8.8	5.7	4.5
	>50 mm	6.1	10.0	0.9	1.8	1.3	0.0	0.0
Swelling	All	29.7	30.0	19.1	13.5	7.9	1.0	1.9
	>50 mm	2.7	6.0	0.9	0.9	1.1	0.0	0.0
General Symptoms, %								
	Type	NIMENRIX N=148	MenC N=50	NIMENRIX N=329	MENACTRA N=326	NIMENRIX N=927	NIMENRIX + FLUARIX N=105	ACWY-PS N=310
Fatigue	All	22.3	22.0	29.2	27.3	12.3	9.5	9.7
	Grade 3	2.7	0.0	2.7	1.5	0.9	0.0	0.0
Fever	All ($\geq 37.5^{\circ}\text{C}$)	6.8	2.0	5.2	4.9	4.0	2.9	4.5
	>39.5°C	0.0	0.0	0.3	0.0	0.2	0.0	0.6
Gastro-intestinal	All	14.9	8.0	13.1	13.5	4.6	1.9	3.2
	Grade 3	0.7	0.0	1.2	1.2	0.2	0.0	0.3
Headache	All	20.3	8.0	26.1	25.5	16.3	13.3	14.2
	Grade 3	1.4	0.0	1.5	1.8	1.5	0.0	1.6

N= number of subjects with the dose documented

%= percentage of subjects reporting the symptom at least once

Study 081 and Study 071: Fever ($\geq 37.5^{\circ}\text{C}$) (Orally)

Study 035: Fever ($\geq 37.5^{\circ}\text{C}$) (Axillary)

Adults > 55 years old

In a descriptive study a single dose of NIMENRIX was administered to 274 individuals aged 56 years and older. The adverse reactions reported in this study were already observed in younger age groups.

Common and Uncommon Clinical Trial Adverse Drug Reactions

Additional adverse reactions reported during clinical studies included in the safety pooled analysis:

Common ($\geq 1\%$ to $< 10\%$)*: Injection site hematoma, gastrointestinal symptoms (including diarrhea, vomiting and nausea)

Uncommon ($\geq 0.1\%$ to $< 1\%$)**: insomnia, crying, hypoesthesia, dizziness, pruritus, rash, urticaria, myalgia, pain in extremity, malaise, and injection site reaction (including induration, pruritus, warmth, anesthesia).

* Nausea and injection site hematoma occurred at a frequency of Uncommon in infants.

** Rash occurred at a frequency of Common in infants. The adverse reactions hypoesthesia, dizziness, pruritus, urticaria, myalgia and pain in extremity were not reported in the infant clinical study (N=524). Urticaria was not reported in the clinical studies of children 6-10 years old (N=990) and adolescents 11-17 years old (N=2317).

Booster Dose in Subjects from 12 Months of Age

The local and general adverse reaction profile of a booster dose of NIMENRIX given to subjects from 12 months of age after primary vaccination with NIMENRIX or other conjugated or plain polysaccharide meningococcal vaccines was similar to the local and general adverse reaction profile observed after primary vaccination with NIMENRIX, except that gastrointestinal symptoms (including diarrhea, vomiting, and nausea) ranged from common to very common among subjects 6 years of age and older (versus common after primary vaccination).

8.5 Post-Market Adverse Reactions

General disorders and administration site conditions

Unknown: extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb.

9 DRUG INTERACTIONS

9.4 Drug-Drug Interactions

Use with Other Vaccines

In infants, NIMENRIX can be given concomitantly with combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and *Haemophilus influenzae* type B vaccines (DTaP/IPV/Hib/HepB), as well as 10-valent pneumococcal conjugate vaccine (PCV10).

From age 1 year and above, NIMENRIX can be given concomitantly with any of the following vaccines: hepatitis A and hepatitis B vaccines (HAV and HBV), measles-mumps-rubella vaccine (MMR), measles-mumps-rubella-varicella vaccine (MMRV), 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.

NIMENRIX can also be given concomitantly with combined diphtheria-tetanus-acellular pertussis vaccines, including combination DTaP vaccines with hepatitis B, inactivated poliovirus or *Haemophilus influenzae* type b, such as DTaP/IPV/Hib/HepB vaccine, and 13-valent pneumococcal conjugate vaccine (PCV13) in the second year of life.

In individuals aged 9 to 25 years, NIMENRIX can be given concomitantly with human papillomavirus bivalent [Type 16 and 18] vaccine, recombinant (HPV2).

Safety and immunogenicity of NIMENRIX was evaluated when sequentially administered or co-administered with a DTaP/IPV/Hib/HepB vaccine in the second year of life. The administration of NIMENRIX 1 month after the DTaP/IPV/Hib/HepB vaccine resulted in lower MenA, MenC and MenW-135 rSBA Geometric Mean Titres (GMTs). The clinical relevance of this observation is unknown, since at least 99.4% of subjects (N=178) had rSBA titres $\geq 1:8$ for each group (A, C, W-135, and Y). Whenever possible, NIMENRIX and a tetanus toxoid (TT) containing vaccine, such as DTaP/IPV/Hib/HepB vaccine, should be co-administered or NIMENRIX should be administered at least 1 month before the TT-containing vaccine.

One month after co-administration with a 10-valent pneumococcal conjugate vaccine, lower Geometric Mean antibody Concentrations (GMCs) and opsonophagocytic assay (OPA) antibody GMTs were observed for one pneumococcal serotype (18C conjugated to tetanus toxoid carrier protein). The clinical relevance of this observation is unknown. There was no impact of co-administration on the other nine pneumococcal serotypes.

One month after co-administration with a combined tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Tdap) in subjects aged 9 to 25 years, lower GMCs were observed to each pertussis antigen (pertussis toxoid [PT], filamentous haemagglutinin [FHA] and pertactin [PRN]). More than 98% of subjects had anti-PT, FHA or PRN concentrations above the assay cut-off thresholds. The clinical relevance of these observations is unknown. There was no impact of co-administration on immune responses to NIMENRIX or the tetanus or diphtheria antigens included in Tdap.

If NIMENRIX is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.

Use with Systemic Immunosuppressive Medications

As with other vaccines, it may be expected that in patients receiving immunosuppressive treatment, an adequate response may not be elicited.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Anti-capsular meningococcal antibodies protect against meningococcal diseases via complement mediated bactericidal killing. NIMENRIX induces the production of bactericidal antibodies against capsular polysaccharides of *Neisseria meningitidis* groups A, C, W-135 and Y when measured by assays using either rabbit complement (rSBA) or human complement (hSBA). By conjugating capsular polysaccharide to a protein carrier that contains T-cell epitopes, meningococcal conjugate vaccines like NIMENRIX change the nature of immune response to capsular polysaccharide from T-cell independent to T-cell dependent.

Canadian epidemiological data is available on the Public Health Agency of Canada website:

<http://www.phac-aspc.gc.ca/im/vpd-mev/meningococcal-eng.php>.

11 STORAGE, STABILITY AND DISPOSAL

Store in a refrigerator (2°C – 8°C). The diluent may also be stored at ambient temperature (25°C).

Do not freeze. Protect from light.

For shelf-life after reconstitution of the vaccine, see [4.3 Reconstitution](#).

12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions for this drug product. For information on reconstitution of the vaccine with the diluent, please see [4.3 Reconstitution](#).

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

NIMENRIX is composed of the purified capsular polysaccharides of *Neisseria meningitidis* groups A, C, W-135 and Y, each conjugated to tetanus toxoid.

14 CLINICAL TRIALS

14.1 Trial Design and Study Demographics

Table 6 Study demographics and trial design

Study #	Study Objectives	Trial design	No. of study subjects [§]	Mean age (Range)	Gender Male/Female
6 weeks-12 months					
Men ACWY-TT - 083	Immunogenicity and safety compared to MenC-CRM and MenC-TT when co-administered with PCV10 and DTaP/IPV/Hib/HepB	Open, randomized, controlled, multi-centre	Total=1841 NIMENRIX: 2 doses=458 3 doses=465 MenC-CRM=459 MenC-TT=459	8.7 weeks (6-12 weeks)	929/912
Men ACWY-TT -087	Immunogenicity and safety of 3 primary + 1 booster dose (2, 4, 6, 15-18 months), 1 primary + 1 booster dose (6, 15-18 months) or 1 dose at 15-18 months (with DTaP-IPV/Hib & PCV10 at 2, 4, 6, 15-18 months)	Open, randomized, controlled, multi-centre	Total=654 NIMENRIX: 3+1 doses =328 1+1 doses =163 1 dose=163	8.0 weeks (6-12 weeks)	320/334
12-23 months					
Men ACWY-TT - 039	Immunogenicity and safety compared to MenC-CRM vaccine and concomitant administration with measles-mumps-rubella-varicella vaccine (MMRV)	Open, randomized, controlled, multi-centre	Total=972 NIMENRIX=366 Co-admin=361 MMRV=121 MenC-CRM=124	14.6 months (12-19 months)	507/465
Men ACWY-TT - 104	Immunogenicity, persistence and safety of 1 and 2 doses and concomitant administration with PCV13	Open, randomized, controlled, multi-centre	Total=802* NIMENRIX: 1 dose=203* 2 doses=197* Co-Admin=201* PCV13=201*	12.8 months (11-15 months)	427/375

Table 6 Study demographics and trial design

Study #	Study Objectives	Trial design	No. of study subjects [§]	Mean age (Range)	Gender Male/Female
2-10 years					
Men ACWY-TT - 081	Immunogenicity and safety compared to MenC-CRM	Open, randomized, controlled, multi-centre	Total=395 NIMENRIX=296 MenC-CRM =99	5.6 years (2-10 years)	191/204
10-55 years					
Men ACWY-TT - 035	Lot-to-lot consistency; immunogenicity and safety compared to ACWY-PS and concomitant administration with influenza virus vaccine	Partially double-blinded, randomized, controlled, multi-centre	Total=1284 NIMENRIX=885 ACWY-PS=294 Co-admin=105	35.5 years (18-55 years)	710/574
Men ACWY-TT - 071	Immunogenicity and safety compared to quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MENACTRA)	Observer-blinded, randomized, controlled, multi-centre	Total=951 NIMENRIX=637 MENACTRA=314	16.3 years (10-25 years)	464/487
> 55 years					
Men ACWY-TT-085	Immunogenicity, safety, and reactogenicity compared to ACWY-PS	Open, randomized, controlled	Total = 260 NIMENRIX= 194 ACWY-PS= 66	63.9 years (56-103 years)	178/82

[§]Number of subjects in according-to-protocol (ATP) cohort for immunogenicity or persistence

*Number of subjects in total vaccinated cohort

14.4 Immunogenicity

Immunogenicity in infants

In Study MenACWY-TT-083, the immunogenicity of a 2-dose primary vaccination schedule (2 and 4 months of age) was evaluated (Table 7). The first dose was administered as early as 6 weeks of age. Routinely used infant vaccines DTaP/IPV/Hib/HepB and a 10-valent pneumococcal vaccine were co-administered. For group C, rSBA and hSBA titres elicited by NIMENRIX were compared to a 2-dose priming with licensed monovalent meningococcal conjugate group C vaccines, MenC-CRM and MenC-TT vaccines. NIMENRIX elicited rSBA and hSBA titres against the four meningococcal groups. The response against group C was non-inferior to the one elicited by the licensed MenC-CRM and MenC-TT vaccines in terms of the percentage of subjects with rSBA titres $\geq 1:8$ at 1 month after the second dose.

For subjects initially vaccinated in infancy with NIMENRIX at 2 and 4 months of age and receiving a NIMENRIX booster dose at 12 months of age, the increase in rSBA and hSBA titres 1 month post-booster dose ranged between 15 and 80-fold for all groups and more than 99.0% of all infants achieved post-booster titres above 8 for both assays (Table 7).

Table 7: Study MenACWY-TT-083: rSBA and hSBA titres following two doses of NIMENRIX (or MenC-CRM or MenC-TT) given 2 months apart with the first dose administered to infants 6-12 weeks of age and following a booster at 12 months of age

Meningo-coccal group	Vaccine group	Time-point*	rSBA**			hSBA***		
			N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
A	NIMENRIX	Post dose 2	456	97.4% (95.4; 98.6)	203 (182; 227)	202	96.5% (93.0; 98.6)	157 (131; 188)
		Post booster	462	99.6% (98.4; 99.9)	1561 (1412.3; 1725.3)	214	99.5% (97.4; 100)	1007.2 (835.7; 1213.8)
C	NIMENRIX	Post dose 2	456	98.7% (97.2; 99.5)	612 (540; 693)	218	98.6% (96.0; 99.7)	1308 (1052; 1627)
		Post booster	463	99.8% (98.8; 100)	1177 (1059.1; 1308)	221	99.5% (97.5; 100)	4992.3 (4085.7; 6100)
	MenC-CRM vaccine	Post dose 2	455	99.6% (98.4; 99.9)	958 (850; 1079)	202	100% (98.2; 100)	3188 (2646; 3841)
		Post booster	446	98.4% (96.8; 99.4)	1051.4 (919.6; 1201.1)	216	100% (98.3; 100)	5438.2 (4412.4; 6702.3)
	MenC-TT vaccine	Post dose 2	457	100% (99.2; 100)	1188 (1080; 1307)	226	100% (98.4; 100)	2626 (2219; 3109)
		Post booster	459	100% (99.2; 100)	1960.2 (1776.4; 2163.1)	219	100% (98.3; 100)	5542.3 (4765.2; 6446.2)
W-135	NIMENRIX	Post dose 2	455	99.1% (97.8; 99.8)	1605 (1383; 1862)	217	100% (98.3; 100)	753 (644; 882)
		Post booster	462	99.8% (98.8; 100)	2777.2 (2485.1; 3103.6)	218	100% (98.3; 100)	5122.7 (4504.2; 5826.1)
Y	NIMENRIX	Post dose 2	456	98.2% (96.6; 99.2)	483 (419; 558)	214	97.7% (94.6; 99.2)	328 (276; 390)
		Post booster	462	99.4% (99.1; 99.9)	881.3 (787.5; 986.4)	217	100% (98.3; 100)	2954 (2497.9; 3493.3)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort.

*Blood sampling performed 1 month post last priming vaccination (dose 2) and 1 month post-booster.

**rSBA analysis performed at Public Health England (PHE) laboratories in UK

***hSBA analysis performed at GSK laboratories

In MenACWY-TT-087, infants received either a single primary dose at 6 months followed by a booster dose at 15-18 months or three primary doses at 2, 4, and 6 months followed by a booster dose at 15-18 months. All subjects also received DTaP-IPV/Hib and 10-valent pneumococcal conjugate vaccines at 2, 4, 6 and 15-18 months of age. The percentage of subjects achieving rSBA titres ≥1:8 for groups A, C, W-135 and Y, after a single primary dose administered at 6 months of age, and after a booster dose, is reported in Table 8.

Table 8: rSBA* and hSBA titres following a single dose of NIMENRIX in infants at 6 months of age and pre- and post-booster at 15-18 months of age (Study MenACWY-TT-087)**

Meningo-coccal Group		rSBA*			hSBA**		
		N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
A	Post dose 1 ⁽¹⁾	163	98.80% (95.6; 99.9)	1332.9 (1035.2; 1716.2)	59	98.30% (90.9; 100)	270.5 (205.9; 355.4)
	Pre Booster	131	81.70% (74; 87.9)	125.3 (84.4; 186.1)	71	66.20% (54; 77)	20.8 (13.5; 32.2)
	Post booster ⁽¹⁾	139	99.30% (96.1; 100)	2762.3 (2310.3; 3302.8)	83	100% (95.7; 100)	1415.6 (1140.2; 1757.5)
C	Post dose 1 ⁽¹⁾	163	99.40% (96.6; 100)	591.6 (482.3; 725.8)	66	100% (94.6; 100)	523.1 (381.5; 717.3)
	Pre Booster	131	65.60% (56.9; 73.7)	27.4 (20.6; 36.6)	78	96.20% (89.2; 99.2)	150.8 (108.5; 209.5)
	Post booster ⁽¹⁾	139	99.30% (96.1; 100)	2525.2 (2102.1; 3033.3)	92	100% (96.1; 100)	13360.1 (10952.9; 16296.4)
W-135	Post dose 1 ⁽¹⁾	163	93.90% (89; 97)	1255.9 (917; 1720)	47	87.20% (74.3; 95.2)	136.5 (78.4; 237.6)
	Pre Booster	131	77.90% (69.8; 84.6)	63.3 (45.6; 87.9)	53	100% (93.3; 100)	428.6 (328.4; 559.2)
	Post booster ⁽¹⁾	139	100% (97.4; 100)	3144.7 (2636.9; 3750.4)	59	100% (93.9; 100)	9015.6 (7045.2; 11537.1)
Y	Post dose 1 ⁽¹⁾	163	98.80% (95.6; 99.9)	1469.9 (1186.5; 1821)	52	92.30% (81.5; 97.9)	194.8 (117.6; 322.9)
	Pre Booster	131	88.50% (81.8; 93.4)	106.4 (76.4; 148.1)	61	98.40% (91.2; 100)	389.2 (292.3; 518.1)
	Post booster ⁽¹⁾	139	100% (97.4; 100)	2748.6 (2301.4; 3282.6)	69	100% (94.8; 100)	5977.6 (4746.8; 7527.6)

The analysis of immunogenicity was conducted on the primary according-to-protocol (ATP) cohort for immunogenicity.
*rSBA analysis performed at Public Health England (PHE) laboratories in UK
**hSBA analysis performed at Neomed, Laval, Canada
⁽¹⁾ blood sampling performed 1 month post vaccination
N = Number of subjects with available results

Serum bactericidal activity was also measured using hSBA as a secondary endpoint. A single primary dose in infants at 6 months was associated with lower hSBA responses to groups W-135 and Y as measured by the percentage of subjects with hSBA titres ≥1:8 [87.2% (95% CI: 74.3, 95.2) and 92.3% (95% CI: 81.5, 97.9), respectively] compared with three primary doses at 2, 4, and 6 months of age [100% (95% CI: 96.6, 100) and 100% (95% CI: 97.1, 100), respectively] (see [7 WARNINGS AND PRECAUTIONS – Immune: Protection Against Meningococcal Disease, Immune response in infants aged 6 months to less than 12 months](#)). After a booster dose, the hSBA titres to all four serogroups were comparable between the two dosing schedules.

Immunogenicity in toddlers aged 12-23 months

In the clinical study MenACWY-TT-039, the immune response to vaccination with either NIMENRIX or a licensed meningococcal C-CRM₁₉₇ conjugate (MenC-CRM) vaccine was evaluated.

A single dose of NIMENRIX elicited rSBA responses against the four meningococcal groups, with a response against group C that was comparable to the one elicited by the licensed MenC-CRM vaccine in term of percentages with rSBA titres $\geq 1:8$ (Table 9)

Table 9 Study MenACWY-TT-039: Percentage of subjects with rSBA^β titres equal to or above the cut off value of 1:8 at day 42 post vaccination

Meningococcal group	N	NIMENRIX (95% CI)	N	Active Control (MenC-CRM)	Difference in percentage (ACWY-TT minus MenC-CRM)* (95%CI)
rSBA-Men A	354	99.7% (98.4; 100)	-	-	-
rSBA-Men C	354	99.7% (98.4; 100)	121	97.5% (92.9; 99.5)	2.20 (0.29; 6.78)
rSBA-MenW-135	354	100% (99.0; 100)	-	-	-
rSBA-Men Y	354	100% (99.0; 100)	-	-	-

N = number of subjects with results available

% = percentage of subjects with titre within the specified range

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

ATP cohort for immunogenicity

*LL of 95% CI is above non-inferiority limit of -10%.

^βSBA analyses performed at GSK Laboratories

The Geometric Mean Titres (GMTs) for MenC 42 days after vaccination were higher in children who received NIMENRIX than those who received MenC-CRM (478 vs. 212). GMTs ranged between 2205 and 2729 for groups A, W-135 and Y in the NIMENRIX group.

In addition this study evaluated the immunogenicity for hSBA prior to and 42 days after the first vaccine dose with NIMENRIX or the control vaccine (MenC-CRM). At 42 days after vaccination, 98.5% of the subjects in the NIMENRIX group and 81.9% of subjects in the MenC-CRM group had hSBA-MenC titres $\geq 1:8$. In the NIMENRIX group the percentage of subjects with hSBA titres $\geq 1:8$ ranged between 77.2% and 87.5 % for groups A, W-135 and Y.

Study MenACWY-TT-104 evaluated the immunogenicity after 1 month and the persistence of the response up to 5 years following 1 or 2 doses (given 2 months apart) of Nimenrix in toddlers aged 12 to 14 months. One month following one or two doses administered (given 2 months apart), Nimenrix elicited rSBA titres against all four meningococcal groups that were similar in terms of the percentage of subjects in both dosing regimens with rSBA titre $\geq 1:8$ and GMT. As a secondary endpoint in the MenACWY-TT-104 study, hSBA titres were measured. In terms of the percentage of subjects with hSBA titres $\geq 1:8$, at 1 month post vaccination, hSBA titres against groups W-135 and Y were higher after two doses of Nimenrix than after one dose, while the hSBA titres against groups A and C were similar for both dosing regimens. At 5 years post vaccination, the immune response for all four meningococcal groups were similar in both the one and two dose groups for both rSBA and hSBA titres $\geq 1:8$ (see Table 10).

Table 10: Study MenACWY-TT-104: rSBA* and hSBA titres following one or two doses of NIMENRIX with the first dose administered to toddlers aged 12-14 months and persistence up to 5 years**

Meningococcal group	NIMENRIX dose group	Timepoint	rSBA ¹			hSBA ¹		
			N	≥1:8 (95%CI)	GMT (95% CI)	N	≥1:8 (95%CI)	GMT (95% CI)
A	1 dose	1 Month Post dose 1	180	97.8% (94.4; 99.4)	1437.0 (1118.3; 1846.6)	74	95.9% (88.6; 99.2)	118.0 (86.8; 160.5)
		1 Year Post Dose 1	167	63.5% (55.7; 70.8)	62.7 (42.6; 92.2)	70	35.7% (24.6; 48.1)	6.1 (4.1; 8.9)
		3 Years Post dose 1	147	46.9% (38.7; 55.3)	29.7 (19.8; 44.5)	55	36.4% (23.8; 50.4)	5.8 (3.8; 8.9)
		5 Years Post dose 1	133	58.6% (49.8; 67.1)	46.8 (30.7; 71.5)	61	27.9% (17.1; 40.8)	4.4 (3.1; 6.2)
	2 doses	1 Month Post dose 1	158	96.8% (92.8; 99.0)	1275.2 (970.5; 1675.4)	66	97.0% (89.5; 99.6)	132.9 (98.1; 180.1)
		1 Month Post dose 2	150	98.0% (94.3; 99.6)	1176.3 (921.8; 1501)	66	97.0% (89.5; 99.6)	170.5 (126.2; 230.2)
		1 Year Post Dose 2	143	70.6% (62.4; 77.9)	76.6 (50.7; 115.7)	62	35.5% (23.7; 48.7)	6.4 (4.2; 10.0)
		3 Years Post dose 2	121	54.5% (45.2; 63.6)	28.5 (18.7; 43.6)	50	36.0% (22.9; 50.8)	5.4 (3.6; 8.0)
		5 Years Post dose 2	117	65.8% (56.5; 74.3)	69.9 (44.7; 109.3)	56	17.9% (8.9; 30.4)	3.1 (2.4; 4.0)
		C	1 dose	1 Month Post dose 1	179	95.0% (90.7; 97.7)	452.3 (345.6; 591.9)	78
1 Year Post Dose 1	167			49.1% (41.3; 56.9)	16.2 (12.4; 21.1)	71	80.3% (69.1; 88.8)	35.2 (22.5; 55.2)
3 Years Post dose 1	147			35.4% (27.7; 43.7)	9.8 (7.6; 12.7)	61	65.6% (52.3; 77.3)	23.6 (13.9; 40.2)
5 Years Post dose 1	132			20.5% (13.9; 28.3)	6.6 (5.3; 8.2)	61	60.7% (47.3; 72.9)	18.1 (10.9; 30.0)
2 doses	1 Month Post dose 1		157	95.5% (91.0; 98.2)	369.3 (280.9; 485.5)	70	95.7% (88.0; 99.1)	160.8 (109.8; 235.5)
	1 Month Post dose 2		150	98.7% (95.3; 99.8)	639.1 (521.8; 782.9)	69	100% (94.8; 100)	1753.3 (1277.7; 2404.2)
	1 Year Post Dose 2		143	55.2% (46.7; 63.6)	21.2 (15.6; 28.9)	63	90.5% (80.4; 96.4)	73.4 (47.5; 113.4)
	3 Years Post dose 2		121	33.9% (25.5; 43.0)	11.5 (8.4; 15.8)	56	67.9% (54.0; 79.7)	27 (15.6; 46.8)
	5 Years Post dose 2		116	28.4% (20.5; 37.6)	8.5 (6.4; 11.2)	59	67.8% (54.4; 79.4)	29.4 (16.3; 52.9)
	W-135		1 dose	1 Month Post dose 1	180	95.0% (90.8; 97.7)	2120.2 (1601.0; 2807.8)	72
1 Year Post Dose 1		167		65.3% (57.5; 72.5)	57.2 (39.9; 82.0)	72	95.8% (88.3; 99.1)	209.0 (149.9; 291.4)
3 Years Post dose 1		147		59.2% (50.8; 67.2)	42.5 (29.2; 61.8)	67	71.6% (59.3; 82.0)	30.5 (18.7; 49.6)
5 Years Post dose 1		133		44.4% (35.8; 53.2)	25 (16.7; 37.6)	56	58.9% (45.0; 71.9)	20.8 (11.6; 37.1)
2 doses		1 Month Post dose 1	158	94.9% (90.3; 97.8)	2030.1 (1510.7; 2728.2)	61	68.9% (55.7; 80.1)	26.2 (16.0; 43.0)
		1 Month Post dose 2	150	100% (97.6; 100)	3533.0 (2914.5; 4282.7)	70	97.1% (90.1; 99.7)	756.8 (550.1; 1041.3)
		1 Year Post Dose 2	143	77.6% (69.9; 84.2)	123.1 (82.7; 183.4)	65	98.5% (91.7; 100.0)	232.6 (168.3; 321.4)

		3 Years Post dose 2	121	72.7% (63.9; 80.4)	92.9 (59.9; 144)	54	87.0% (75.1; 94.6)	55.5 (35.3; 87.1)
		5 Years Post dose 2	117	50.4% (41.0; 59.8)	37.1 (23.3; 59.0)	44	63.6% (47.8; 77.6)	19.5 (10.7; 35.2)
Y	1 dose	1 Month Post dose 1	180	92.8% (88.0; 96.1)	951.8 (705.0; 1284.9)	71	67.6% (55.5; 78.20)	41.2 (23.7; 71.5)
		1 Year Post Dose 1	167	73.1% (65.7; 79.6)	76.8 (54.2; 109.0)	62	91.9% (82.2; 97.3)	144.4 (97.2; 214.5)
		3 Years Post dose 1	147	61.9% (53.5; 69.8)	58 (39.1; 86.0)	64	53.1% (40.2; 65.7)	17.3 (10.1; 29.6)
		5 Years Post dose 1	133	47.4% (38.7; 56.2)	36.5 (23.6; 56.2)	65	61.5% (48.6; 73.3)	24.3 (14.3; 41.1)
	2 doses	1 Month Post dose 1	157	93.6% (88.6; 96.9)	933.3 (692.3; 1258.3)	56	64.3% (50.4; 76.6)	31.9 (17.6; 57.9)
		1 Month Post dose 2	150	99.3% (96.3; 100)	1133.6 (944.5; 1360.5)	64	95.3% (86.9; 99.0)	513.0 (339.4; 775.4)
		1 Year Post Dose 2	143	79.7% (72.2; 86.0)	112.3 (77.5; 162.8)	58	87.9% (76.7; 95.0)	143.9 (88.5; 233.8)
		3 Years Post dose 2	121	68.6% (59.5; 76.7)	75.1 (48.7; 115.9)	52	61.5% (47.0; 74.7)	24.1 (13.3; 43.8)
		5 Years Post dose 2	117	58.1% (48.6; 67.2)	55.8% (35.7; 87.5)	48	54.2% (39.2; 68.6)	16.8 (9.0; 31.3)

The analysis of immunogenicity was conducted on the according-to-protocol (ATP) cohort for immunogenicity
¹ blood sampling performed 21 to 48 days post vaccination and 44 to 60 weeks post vaccination.

*rSBA analysis performed at Public Health England laboratories

**hSBA analysis performed at GSK laboratories

N = Number of subjects with available results

Persistence of immune response in toddlers aged 12-23 months

In Study MenACWY-TT-048, the persistence of rSBA and hSBA titres was evaluated up to four years in toddlers in terms of percentage of subjects with antibody titres $\geq 1:8$ for each of the 4 groups in toddlers primed in Study MenACWY-TT-039.

Forty-eight months following primary vaccination, 27% of the children were included in this evaluation (Table 11).

Table 11 rSBA and hSBA titres up to 4 years following NIMENRIX (or MenC-CRM) in toddlers aged 12-23 months (Study MenACWY-TT-048)

Meningo-coccal group	Vaccine group	Time-point (Year)	rSBA*		hSBA**	
			N	% Response	N	% Response
A	NIMENRIX	3	262	59.9%	251	35.9%
		4	224	74.1%	198	28.8%
C	NIMENRIX	3	262	35.9%	253	78.3%
		4	225	40.4%	209	73.2%
	MenC-CRM vaccine	3	46	13.0%	31	41.9%
		4	45	35.6%	32	46.9%
W-135	NIMENRIX	3	261	49.8%	254	82.3%
		4	225	49.3%	165	80.6%
Y	NIMENRIX	3	262	53.8%	250	72.0%
		4	225	58.2%	130	65.4%

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each time-point.

*rSBA analysis performed at Public Health England (PHE) laboratories in UK

**hSBA analysis performed at GSK laboratories

Vaccine response defined as: post-vaccination antibody titre $\geq 1:8$

rSBA and hSBA titres were determined over a period of 10 years in children initially vaccinated with one dose of NIMENRIX or MenC-CRM at 12 to 23 months of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of NIMENRIX administered 10 years following the initial vaccination with NIMENRIX or MenC-CRM. Results are shown in Table 12.

Table 12: rSBA and hSBA titres following a single dose of NIMENRIX (or MenC-CRM) in toddlers aged 12-23 months, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	$\geq 1:8$ (95% CI)	GMT (95% CI)	N	$\geq 1:8$ (95% CI)	GMT (95% CI)
A	NIMENRIX	Month 1 ⁽¹⁾	222	100% (98.4; 100)	3707 (3327; 4129)	217	91.2% (86.7; 94.6)	59.0 (49.3; 70.6)
		Year 4 ⁽²⁾	45	64.4% (48.8; 78.1)	35.1 (19.4; 63.4)	44	52.3% (36.7; 67.5)	8.8 (5.4; 14.2)
		Year 5 ⁽²⁾	49	73.5% (58.9; 85.1)	37.4 (22.1; 63.2)	45	35.6% (21.9; 51.2)	5.2 (3.4; 7.8)
		Year 10 ⁽³⁾ (Pre-booster)	62	66.1% (53.0; 77.7)	28.9 (16.4; 51.0)	59	25.4% (15.0; 38.4)	4.2 (3.0; 5.9)
		(Post-booster) ^(3,4)	62	98.4% (91.3; 100)	5122 (3726; 7043)	62	100% (94.2; 100)	1534 (1112; 2117)

Table 12: rSBA and hSBA titres following a single dose of NIMENRIX (or MenC-CRM) in toddlers aged 12-23 months, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
C	NIMENRIX	Month 1 ⁽¹⁾	220	100% (98.3; 100)	879 (779; 991)	221	99.1% (96.8; 99.9)	190 (165; 219)
		Year 4 ⁽²⁾	45	97.8% (88.2; 99.9)	110 (62.7; 192)	45	97.8% (88.2; 99.9)	370 (214; 640)
		Year 5 ⁽²⁾	49	77.6% (63.4; 88.2)	48.9 (28.5; 84.0)	48	91.7% (80.0; 97.7)	216 (124; 379)
		Year 10 ⁽³⁾ (Pre-booster)	62	82.3% (70.5; 90.8)	128 (71.1; 231)	60	91.7% (81.6; 97.2)	349 (197; 619)
		(Post-booster) ^(3,4)	62	100% (94.2; 100)	7164 (5478; 9368)	59	100% (93.9; 100)	33960 (23890; 48274)
	MenC-CRM vaccine	Month 1 ⁽¹⁾	68	98.5% (92.1; 100)	415 (297; 580)	68	72.1% (59.9; 82.3)	21.2 (13.9; 32.3)
		Year 4 ⁽²⁾	10	80.0% (44.4; 97.5)	137 (22.6; 832)	10	70.0% (34.8; 93.3)	91.9 (9.8; 859)
		Year 5 ⁽²⁾	11	63.6% (30.8; 89.1)	26.5 (6.5; 107)	11	90.9% (58.7; 99.8)	109 (21.2; 557)
		Year 10 ⁽³⁾ (Pre-booster)	16	87.5% (61.7; 98.4)	86.7 (29.0; 259)	15	93.3% (68.1; 99.8)	117 (40.0; 344)
		(Post-booster) ^(3,4)	16	100% (79.4; 100)	5793 (3631; 9242)	15	100% (78.2; 100)	42559 (20106; 90086)
W-135	NIMENRIX	Month 1 ⁽¹⁾	222	100% (98.4; 100)	5395 (4870; 5976)	177	79.7% (73.0; 85.3)	38.8 (29.7; 50.6)
		Year 4 ⁽²⁾	45	60.0% (44.3; 74.3)	50.8 (24.0; 108)	45	84.4% (70.5; 93.5)	76.9 (44.0; 134)
		Year 5 ⁽²⁾	49	34.7% (21.7; 49.6)	18.2 (9.3; 35.3)	46	82.6% (68.6; 92.2)	59.7 (35.1; 101)
		Year 10 ⁽³⁾ (Pre-booster)	62	30.6% (19.6; 43.7)	15.8 (9.1; 27.6)	52	44.2% (30.5; 58.7)	7.7 (4.9; 12.2)
		(Post-booster) ^(3,4)	62	100% (94.2; 100)	25911 (19120; 35115)	62	100% (94.2; 100)	11925 (8716; 16316)
Y	NIMENRIX	Month 1 ⁽¹⁾	222	100% (98.4; 100)	2824 (2529; 3153)	201	66.7% (59.7; 73.1)	24.4 (18.6; 32.1)
		Year 4 ⁽²⁾	45	62.2% (46.5; 76.2)	44.9 (22.6; 89.3)	41	87.8% (73.8; 95.9)	74.6 (44.5; 125)
		Year 5 ⁽²⁾	49	42.9% (28.8; 57.8)	20.6 (10.9; 39.2)	45	80.0% (65.4; 90.4)	70.6 (38.7; 129)
		Year 10 ⁽³⁾ (Pre-booster)	62	45.2% (32.5; 58.3)	27.4 (14.7; 51.0)	56	42.9% (29.7; 56.8)	9.1 (5.5; 15.1)
		(Post-booster) ^(3,4)	62	98.4% (91.3; 100)	7661 (5263; 11150)	61	100% (94.1; 100)	12154 (9661; 15291)

The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort.

- (1) Study MenACWY-TT-027
- (2) Study MenACWY-TT-032
- (3) Study MenACWY-TT-100
- (4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post-primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.

**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT-100.

Persistence of booster response

Study MenACWY-TT-102 evaluated the persistence of SBA titres up to 6 years after a booster dose of NIMENRIX or MenC-CRM₁₉₇ administered in Study MenACWY-TT-048 to children who initially received the same vaccine at 12 to 23 months of age in Study MenACWY-TT-039. A single booster dose was administered 4 years after the initial vaccination. Results are shown in Table 13.

Table 13: rSBA and hSBA titres following a single dose of NIMENRIX (or MenC-CRM) in toddlers aged 12-23 months, persistence at 4 years and response following a booster 4 years after initial vaccination, and persistence up to 6 years following booster vaccination (Studies MenACWY-TT-039/048/102)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
A	NIMENRIX	Month 1 ⁽¹⁾	354	99.7% (98.4; 100)	2205 (2008; 2422)	338	77.2% (72.4; 81.6)	19.0 (16.4; 22.1)
		Year 4 ⁽²⁾ (Pre-NIMENRIX booster)	212	74.5% (68.1; 80.2)	112 (80.3; 156)	187	28.9% (22.5; 35.9)	4.8 (3.9; 5.9)
		(Post-booster) ^(2,3)	214	100% (98.3; 100)	7173 (6389; 8054)	202	99.5% (97.3; 100)	1343 (1119; 1612)
		5 years after booster dose ⁽⁴⁾	137	89.8% (83.4; 94.3)	229 (163; 322)	135	53.3% (44.6; 62.0)	13.2 (9.6; 18.3)
		6 years after booster dose ⁽⁴⁾	134	92.5% (86.7; 96.4)	297 (214; 413)	130	58.5% (49.5; 67.0)	14.4 (10.5; 19.7)
C	NIMENRIX	Month 1 ⁽¹⁾	354	99.7% (98.4; 100)	478 (437; 522)	341	98.5% (96.6; 99.5)	196 (175; 219)
		Year 4 ⁽²⁾ (Pre-NIMENRIX booster)	213	39.9% (33.3; 46.8)	12.1 (9.6; 15.2)	200	73.0% (66.3; 79.0)	31.2 (23.0; 42.2)
		(Post-booster) ^(2,3)	215	100% (98.3; 100)	4512 (3936; 5172)	209	100% (98.3; 100)	15831 (13626; 18394)
		5 years after booster dose ⁽⁴⁾	137	80.3% (72.6; 86.6)	66.0 (48.1; 90.5)	136	99.3% (96.0; 100)	337 (261; 435)
		6 years after booster dose ⁽⁴⁾	134	71.6% (63.2; 79.1)	39.6 (28.6; 54.6)	130	97.7% (93.4; 99.5)	259 (195; 345)
	MenC-CRM vaccine	Month 1 ⁽¹⁾	121	97.5% (92.9; 99.5)	212 (170; 265)	116	81.9% (73.7; 88.4)	40.3 (29.5; 55.1)
		Year 4 ⁽²⁾ (Pre-MenC-CRM ₁₉₇ booster)	43	37.2% (23.0; 53.3)	14.3 (7.7; 26.5)	31	48.4% (30.2; 66.9)	11.9 (5.1; 27.6)
		(Post-booster) ^(2,3)	43	100% (91.8; 100)	3718 (2596; 5326)	33	100% (89.4; 100)	8646 (5887; 12699)
		5 years after booster dose ⁽⁴⁾	23	78.3% (56.3; 92.5)	47.3 (19.0; 118)	23	100% (85.2; 100)	241 (139; 420)
		6 years after booster dose ⁽⁴⁾	23	65.2% (42.7; 83.6)	33.0 (14.7; 74.2)	23	95.7% (78.1; 99.9)	169 (94.1; 305)

Table 13: rSBA and hSBA titres following a single dose of NIMENRIX (or MenC-CRM) in toddlers aged 12-23 months, persistence at 4 years and response following a booster 4 years after initial vaccination, and persistence up to 6 years following booster vaccination (Studies MenACWY-TT-039/048/102)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
W-135	NIMENRIX	Month 1 ⁽¹⁾	354	100% (99.0; 100)	2682 (2453; 2932)	336	87.5% (83.5; 90.8)	48.9 (41.2; 58.0)
		Year 4 ⁽²⁾ (Pre-NIMENRIX booster)	213	48.8% (41.9; 55.7)	30.2 (21.9; 41.5)	158	81.6% (74.7; 87.3)	48.3 (36.5; 63.9)
		(Post-booster) ^(2,3)	215	100% (98.3; 100)	10950 (9531; 12579)	192	100% (98.1; 100)	14411 (12972; 16010)
		5 years after booster dose ⁽⁴⁾	137	88.3% (81.7; 93.2)	184 (130; 261)	136	100% (97.3; 100)	327 (276; 388)
		6 years after booster dose ⁽⁴⁾	134	85.8% (78.7; 91.2)	172 (118; 251)	133	98.5% (94.7; 99.8)	314 (255; 388)
Y	NIMENRIX	Month 1 ⁽¹⁾	354	100% (99.0; 100)	2729 (2473; 3013)	329	79.3% (74.5; 83.6)	30.9 (25.8; 37.1)
		Year 4 ⁽²⁾ (Pre-NIMENRIX booster)	213	58.2% (51.3; 64.9)	37.3 (27.6; 50.4)	123	65.9% (56.8; 74.2)	30.2 (20.2; 45.0)
		(Post-booster) ^(2,3)	215	100% (98.3; 100)	4585 (4129; 5093)	173	100% (97.9; 100)	6776 (5961; 7701)
		5 years after booster dose ⁽⁴⁾	137	92.7% (87.0; 96.4)	265 (191; 368)	137	97.8% (93.7; 99.5)	399 (321; 495)
		6 years after booster dose ⁽⁴⁾	134	94.0% (88.6; 97.4)	260 (189; 359)	131	97.7% (93.5; 99.5)	316 (253; 394)

The analysis of immunogenicity was conducted on the ATP cohort for each time point.

- (1) Study MenACWY-TT-039
- (2) Study MenACWY-TT-048
- (3) Blood sampling was performed 1 month after a booster dose at Year 4.
- (4) Study MenACWY-TT-102

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT-102.

Immune memory

In Study MenACWY-TT-014, the induction of immune memory was assessed 1 month after the administration of a fifth of the dose of ACWY-PS vaccine (10 mcg of each polysaccharide) to children in the third year of life initially vaccinated in Study MenACWY-TT-013 with NIMENRIX or a licensed MenC-CRM vaccine at the age of 12 to 14 months.

One month after the challenge dose, the GMTs elicited by the initial vaccination with NIMENRIX increased by 6.1 to 34 fold for groups A, C, W-135 and Y, indicating that NIMENRIX induces immune memory to all four meningococcal groups. The post-challenge rSBA-MenC GMT was similar in both study groups, indicating that NIMENRIX induces an analogous immune memory to group C as the licensed MenC-CRM vaccine (Table 14).

Table 14 rSBA* titres 1 month after a challenge vaccination in subjects initially vaccinated with NIMENRIX (or a MenC-CRM vaccine) at the age of 12 to 14 months (Study MenACWY-TT-014)

Meningococcal group	Vaccine group	Pre-challenge		Post-challenge	
		N	GMT	N	GMT
A	NIMENRIX	32	544	25	3322
C	NIMENRIX	31	174	32	5966
	MenC-CRM vaccine	28	34	30	5265
W-135	NIMENRIX	32	644	32	11058
Y	NIMENRIX	32	440	32	5737

The analysis of immunogenicity was conducted on the ATP cohort.

*rSBA analysis performed at GSK Laboratories

Immunogenicity in children aged 2 to 10 years

In Study (MenACWY-TT-081) conducted in subjects aged 2-10 years, one group of subjects received a dose of NIMENRIX and a second group a dose of a licensed MenC-CRM vaccine as a comparator.

Table 15 Study MenACWY-TT-081: Percentage of subjects with a vaccine response in terms of rSBA* antibodies one month following vaccination

Meningococcal group	N	NIMENRIX % (95% CI)	N	Active Control (MenC-CRM) % (95% CI)	Difference in vaccine response rate (ACWY-TT minus MenC-CRM) (95%CI)*
rSBA-Men A	226	94.7% (90.9; 97.2)	-	-	-
rSBA-Men C	268	94.8% (91.4; 97.1)	92	95.7% (89.2; 98.8)	-0.88 (-5.25; 5.57)
rSBA-MenW-135	282	98.6% (96.4; 99.6)	-	-	-
rSBA-Men Y	285	96.5% (93.6; 98.3)	-	-	-

Vaccine response defined as:

For initially seronegative subjects: post-vaccination antibody titre \geq 1:32 at 1 month post-vaccination

For initially seropositive subjects: antibody titre at 1 month post-vaccination \geq 4 fold the pre-vaccination antibody titre

N = number of subjects with pre- and post-vaccination results available

95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Bold: LL of 95% CI is above non-inferiority limit of -10% for MenC.

*tested at GSK Laboratories

The non-inferiority of the NIMENRIX vaccine compared to the MenC-CRM vaccine in terms of serum bactericidal antibody vaccine response to rSBA-MenC, 1 month after vaccination was demonstrated since the lower limit of the 95% CIs on the difference between the NIMENRIX and (minus) the MenC-CRM group was -5.25%, which was above the pre-specified non-inferiority limit of -10%.

The GMT elicited by MenC-CRM was higher than the one observed for the NIMENRIX vaccine (5291.6 vs. 2794.8). The percentage of subjects with rSBA-MenC titre \geq 1:128 was similar for both vaccines (100% vs. 99.3%). For NIMENRIX GMTs ranged between 6236.1 and 8549.5 for rSBA MenA, W-135 and Y.

Persistence of immune response in children aged 2-10 years

In Study MenACWY-TT-088 (Table 16), the persistence of the SBA titres was evaluated by rSBA and hSBA up to 68 months after vaccination in children 2-10 years of age initially vaccinated in Study MenACWY-TT-081 (Table 15).

Table 16 rSBA and hSBA titres up to 68 months following NIMENRIX (or MenC-CRM) in children aged 2-10 years at time of vaccination (Study MenACWY-TT-088)

Meningo-coccal group	Vaccine group	Timepoint (months)	rSBA*		hSBA**	
			N	% response	N***	% response
A	NIMENRIX	32	193	86.5%	90	25.6%
		44	189	85.7%	89	25.8%
		68	178	86.5%	170	40.6%
C	NIMENRIX	32	192	64.6%	90	95.6%
		44	189	37.0%	82	76.8%
		68	178	39.9%	172	75.6%
	MenC-CRM vaccine	32	69	76.8%	33	90.9%
		44	66	45.5%	31	64.5%
		68	61	62.3%	57	75.4%
W-135	NIMENRIX	32	193	77.2%	86	84.9%
		44	189	68.3%	87	80.5%
		68	178	52.8%	159	78.6%
Y	NIMENRIX	32	193	81.3%	91	81.3%
		44	189	62.4%	76	82.9%
		68	178	71.3%	159	73.0%

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each timepoint.

*rSBA analysis performed at PHE laboratories in UK

** hSBA analysis performed at GSK laboratories

***at Month 32, a subset of subjects was tested for hSBA

Vaccine response defined as: post-vaccination antibody titre \geq 1:8

SBA titres were determined over a period of 10 years in children initially vaccinated with one dose of NIMENRIX or ACWY-PS at 2 to 10 years of age in Study MenACWY-TT-027. Persistence of SBA titres was evaluated in two extension studies: MenACWY-TT-032 (up to 5 years) and MenACWY-TT-100 (up to 10 years). Study MenACWY-TT-100 also evaluated the response to a single booster dose of NIMENRIX administered 10 years following the initial vaccination with NIMENRIX or ACWY-PS. Results are shown in Table 17.

Table 17: rSBA and hSBA titres following a single dose of NIMENRIX (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
A	NIMENRIX	Month 1 ⁽¹⁾	225	100% (98.4; 100)	7301 (6586; 8093)	111 ⁽⁵⁾	81.1% (72.5; 87.9)	57.0 (40.3; 80.6)
		Year 5 ⁽²⁾	98	90.8% (83.3; 95.7)	141 (98.2; 203)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	98	79.6% (70.3; 87.1)	107 (66.0; 174)	90	41.1% (30.8; 52.0)	6.5 (4.8; 8.8)
		Year 10 ⁽³⁾ (Pre-booster)	73	89.0% (79.5; 95.1)	96.3 (57.1; 163)	62	33.9% (22.3; 47.0)	4.5 (3.3; 6.2)
		(Post-booster) ^(3,4)	74	95.9% (88.6; 99.2)	4626 (3041; 7039)	73	100% (95.1; 100)	1213 (994; 1481)
	ACWY-PS vaccine	Month 1 ⁽¹⁾	75	100% (95.2; 100)	2033 (1667; 2480)	35 ⁽⁵⁾	25.7% (12.5; 43.3)	4.1 (2.6; 6.5)
		Year 5 ⁽²⁾	13	15.4% (1.9; 45.4)	4.7 (3.7; 6.0)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	24	12.5% (2.7; 32.4)	5.8 (3.5; 9.6)	21	33.3% (14.6; 57.0)	5.9 (3.0; 11.7)
		Year 10 ⁽³⁾ (Pre-booster)	17	23.5% (6.8; 49.9)	8.0 (3.3; 19.3)	17	29.4% (10.3; 56.0)	6.2 (2.4; 15.7)
		(Post-booster) ^(3,4)	17	100% (80.5; 100)	6414 (3879; 10608)	17	100% (80.5; 100)	211 (131; 340)
C	NIMENRIX	Month 1 ⁽¹⁾	225	100% (98.4; 100)	2435 (2106; 2816)	107 ⁽⁵⁾	89.7% (82.3; 94.8)	155 (101; 237)
		Year 5 ⁽²⁾	98	90.8% (83.3; 95.7)	79.7 (56.0; 113)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	98	82.7% (73.7; 89.6)	193 (121; 308)	97	93.8% (87.0; 97.7)	427 (261; 700)
		Year 10 ⁽³⁾ (Pre-booster)	74	85.1% (75.0; 92.3)	181 (106; 310)	73	91.8% (83.0; 96.9)	222 (129; 380)
		(Post-booster) ^(3,4)	74	100% (95.1; 100)	4020 (3319; 4869)	71	100% (94.9; 100)	15544 (11735; 20588)
	ACWY-PS vaccine	Month 1 ⁽¹⁾	74	100% (95.1; 100)	750 (555; 1014)	38 ⁽⁵⁾	39.5% (24.0; 56.6)	13.1 (5.4; 32.0)
		Year 5 ⁽²⁾	13	100% (75.3; 100)	128 (56.4; 291)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	24	79.2% (57.8; 92.9)	98.7 (42.2; 231)	24	100% (85.8; 100)	235 (122; 451)
		Year 10 ⁽³⁾ (Pre-booster)	17	76.5% (50.1; 93.2)	96.2 (28.9; 320)	17	100% (80.5; 100)	99.1 (35.8; 274)
		(Post-booster) ^(3,4)	17	100% (80.5; 100)	15101 (7099; 32122)	17	94.1 (71.3; 99.9)	44794 (10112; 198440)

Table 17: rSBA and hSBA titres following a single dose of NIMENRIX (or ACWY-PS) in children aged 2-10 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-027/032/100)

Meningo-coccal group	Vaccine group	Time point	rSBA*			hSBA**		
			N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
W-135	NIMENRIX	Month 1 ⁽¹⁾	225	100% (98.4; 100)	11777 (10666; 13004)	107 ⁽⁵⁾	95.3% (89.4; 98.5)	134 (101; 178)
		Year 5 ⁽²⁾	98	78.6% (69.1; 86.2)	209 (128; 340)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	98	73.5% (63.6; 81.9)	265 (155; 454)	92	81.5% (72.1; 88.9)	62.5 (42.0; 93.1)
		Year 10 ⁽³⁾ (Pre-booster)	74	68.9% (57.1; 79.2)	206 (109; 392)	59	61.0% (47.4; 73.5)	17.5 (10.5; 29.2)
		(Post-booster) ^(3,4)	74	100% (95.1; 100)	27944 (22214; 35153)	74	100% (95.1; 100)	6965 (5274; 9198)
	ACWY-PS vaccine	Month 1 ⁽¹⁾	75	100% (95.2; 100)	2186 (1723; 2774)	35 ⁽⁵⁾	34.3% (19.1; 52.2)	5.8 (3.3; 9.9)
		Year 5 ⁽²⁾	13	0% (0.0; 24.7)	4.0 (4.0; 4.0)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	24	12.5% (2.7; 32.4)	7.6 (3.7; 15.6)	23	30.4% (13.2; 52.9)	7.0 (2.9; 16.9)
		Year 10 ⁽³⁾ (Pre-booster)	17	23.5% (6.8; 49.9)	15.4 (4.2; 56.4)	15	26.7% (7.8; 55.1)	4.1 (2.0; 8.5)
		(Post-booster) ^(3,4)	17	94.1% (71.3; 99.9)	10463 (3254; 33646)	15	100% (78.2; 100)	200 (101; 395)
Y	NIMENRIX	Month 1 ⁽¹⁾	225	100% (98.4; 100)	6641 (6044; 7297)	94 ⁽⁵⁾	83.0% (73.8; 89.9)	93.7 (62.1; 141)
		Year 5 ⁽²⁾	98	78.6% (69.1; 86.2)	143 (88.0; 233)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	98	71.4% (61.4; 80.1)	136 (82.6; 225)	89	65.2% (54.3; 75.0)	40.3 (23.9; 68.1)
		Year 10 ⁽³⁾ (Pre-booster)	74	67.6% (55.7; 78.0)	98.5 (54.3; 179)	65	72.3% (59.8; 82.7)	35.7 (21.0; 60.6)
		(Post-booster) ^(3,4)	74	100% (95.1; 100)	7530 (5828; 9729)	74	100% (95.1; 100)	11127 (8909; 13898)
	ACWY-PS vaccine	Month 1 ⁽¹⁾	75	100% (95.2; 100)	1410 (1086; 1831)	32 ⁽⁵⁾	43.8% (26.4; 62.3)	12.5 (5.6; 27.7)
		Year 5 ⁽²⁾	13	7.7% (0.2; 36.0)	5.5 (2.7; 11.1)	n/a ⁽⁶⁾	--	--
		Year 6 ⁽³⁾	24	20.8% (7.1; 42.2)	11.6 (4.7; 28.7)	24	25.0% (9.8; 46.7)	7.3 (2.7; 19.8)
		Year 10 ⁽³⁾ (Pre-booster)	17	17.6% (3.8; 43.4)	10.2 (3.5; 30.2)	14	35.7% (12.8; 64.9)	7.8 (2.5; 24.4)
		(Post-booster) ^(3,4)	17	100% (80.5; 100)	6959 (3637; 13317)	17	100% (80.5; 100)	454 (215; 960)

The analysis of immunogenicity was conducted on the ATP cohort for each time point.

- (1) Study MenACWY-TT-027
- (2) Study MenACWY-TT-032
- (3) Study MenACWY-TT-100
- (4) Blood sampling was performed 1 month after a booster dose at Year 10.

(5) Includes children aged 6 to <11 years. hSBA analysis was not performed for children aged 2 to <6 years (at time of vaccination).

(6) Per the protocol for Study MenACWY-TT-032, hSBA was not measured for this age group at Year 5.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for subsequent sampling time points.

**hSBA analysis performed at GSK laboratories and at Neomed in Canada for time points in Study MenACWY-TT-100.

Immunogenicity in adolescents/adults aged 10-25 years and adults aged 18 up to 55 years

In a Phase II head-to-head study conducted in Canada and the US with NIMENRIX and the licensed quadrivalent meningococcal diphtheria toxoid conjugate vaccine (ACWY-DT) MENACTRA in subjects aged 10-25 years (Study Men ACWY-TT-071), either one dose of NIMENRIX or one dose of MENACTRA was administered.

NIMENRIX was demonstrated to be immunologically non-inferior to MENACTRA in terms of the percentage of subjects with hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY vaccine response 1 month after vaccination (all the lower limits of the two-sided 95% CI for the difference between groups were greater than or equal to -10%) (Table 18).

The GMT elicited by NIMENRIX ranged from 49.6 to 755.8 for hSBA MenA, C, W-135 and Y and the GMT elicited by MENACTRA ranged from 41.3 to 543.4 for hSBA MenA, C, W-135 and Y.

Table 18 Study Men ACWY-TT-071: Percentage of subjects with vaccine response to hSBA* antibodies 1 month following vaccination

Meningococcal group	N	NIMENRIX % (95% CI)	N	MENACTRA % (95% CI)	Difference in vaccine response rate (ACWY-TT Lot A minus ACWY-DT)* (95%CI)
hSBA-Men A	310	70.3% (64.9; 75.4)	297	64.3% (58.6; 69.8)	6.01 (-1.45; 13.44)
hSBA-Men C	281	77.2% (71.9; 82.0)	274	76.3% (70.8; 81.2)	0.95 (-6.10; 8.00)
hSBA-MenW-135	279	71.0% (65.3; 76.2)	289	64.0% (58.2; 69.6)	6.95 (-0.76; 14.59)
hSBA-Men Y	293	51.2% (45.3; 57.1)	295	39.0% (33.4; 44.8)	12.21 (4.17; 20.10)

Vaccine response defined as:

For initially seronegative subjects: post-vaccination antibody titre $\geq 1:8$ at 1 month post-vaccination

For initially seropositive subjects: antibody titre at 1 month post-vaccination ≥ 4 -fold the pre-vaccination antibody titre

N = number of subjects with pre- and post-vaccination results available

95% CI = Standardized asymptotic 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Bold: LL of 95% CI is above non-inferiority limit of -10%.

*hSBA analysis performed at GSK Laboratories

In another clinical study, conducted in adults 18-55 years of age (Study MenACWY-TT-035), either one dose of NIMENRIX or one dose of the ACWY-PS vaccine were administered.

Table 19 Study MenACWY-TT-035: Percentage of subjects with vaccine response to rSBA* antibodies 1 month following vaccination

Meningococcal group	N	NIMENRIX % (95% CI)	N	Active Control (ACWY-PS) % (95% CI)	Difference in vaccine response rate (NIMENRIX minus ACWY-PS) (95%CI)*
rSBA-Men A	743	80.1% (77.0; 82.9)	252	69.8% (63.8; 75.4)	10.24 (4.11; 16.78)
rSBA-Men C	849	91.5% (89.4; 93.3)	288	92.0% (88.3; 94.9)	-0.49 (-3.85; 3.57)
rSBA-MenW-135	860	90.2% (88.1; 92.1)	283	85.5% (80.9; 89.4)	4.72 (0.49; 9.65)
rSBA-Men Y	862	87.0% (84.6; 89.2)	288	78.8% (73.6; 83.4)	8.19 (3.24; 13.69)

Vaccine response defined as:

For initially seronegative subjects (i.e., pre-vaccination rSBA titre <1:8): post-vaccination antibody titre \geq 1:32 at 1 month post-vaccination

For initially seropositive subjects (i.e., pre-vaccination rSBA titre \geq 1:8): antibody titre at 1 month post-vaccination \geq 1:4 fold the pre-vaccination antibody titre

N = number of subjects with pre- and post-vaccination results available

95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Bold: LL of 95% CI is above non-inferiority limit of -10%

* rSBA analysis performed at GSK Laboratories

The response to the four meningococcal groups elicited by NIMENRIX was either similar or higher than the one elicited by the ACWY-PS vaccine. In adults, NIMENRIX was demonstrated to be immunologically non-inferior to the ACWY-PS vaccine. NIMENRIX induced higher GMTs and vaccine response for groups A, W-135 and Y than the ACWY-PS vaccine. The GMT elicited by NIMENRIX ranged from 3624.7 to 8865.9 for rSBA MenA, C, W-135 and Y and the GMT elicited by MENACTRA ranged from 2127.2 to 7371.2 for rSBA MenA, C, W-135 and Y.

rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of NIMENRIX or ACWY-PS at 11 to 17 years of age in Study MenACWY-TT-036. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-043 (up to 5 years) and MenACWY-TT-101 (at 10 years). Study MenACWY-TT-101 also evaluated the response to a single booster dose of NIMENRIX administered 10 years following the initial vaccination with NIMENRIX or ACWY-PS. Results are shown in Table 20.

Table 20: rSBA* titres following a single dose of NIMENRIX (or ACWY-PS) in adolescents aged 11-17 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-036/043/101)

Meningo-coccal group	Time point	NIMENRIX			ACWY-PS vaccine		
		N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
A	Month 1 ⁽¹⁾	674	100% (99.5; 100)	5929 (5557; 6324)	224	99.6% (97.5; 100)	2947 (2612; 3326)
	Year 3 ⁽²⁾	449	92.9% (90.1; 95.1)	448 (381; 527)	150	82.7% (75.6; 88.4)	206 (147; 288)
	Year 5 ⁽²⁾	236	97.5% (94.5; 99.1)	644 (531; 781)	86	93.0% (85.4; 97.4)	296 (202; 433)
	Year 10 ⁽³⁾ (Pre-booster)	162	85.2% (78.8; 90.3)	248 (181; 340)	51	80.4% (66.9; 90.2)	143 (80.5; 253)
	(Post-booster) ^(3,4)	162	100% (97.7; 100)	3760 (3268; 4326)	51	100% (93.0; 100)	2956 (2041; 4282)
C	Month 1 ⁽¹⁾	673	100% (99.5; 100)	13110 (11939; 14395)	224	100% (98.4; 100)	8222 (6808; 9930)
	Year 3 ⁽²⁾	449	91.1% (88.1; 93.6)	371 (309; 446)	150	86.0% (79.4; 91.1)	390 (262; 580)
	Year 5 ⁽²⁾	236	88.6% (83.8; 92.3)	249 (194; 318)	85	87.1% (78.0; 93.4)	366 (224; 599)
	Year 10 ⁽³⁾ (Pre-booster)	162	90.1% (84.5; 94.2)	244 (182; 329)	51	82.4% (69.1; 91.6)	177 (86.1; 365)
	(Post-booster) ^(3,4)	162	100% (97.7; 100)	8698 (7391; 10235)	51	100% (93.0; 100)	3879 (2715; 5544)
W-135	Month 1 ⁽¹⁾	678	99.9% (99.2; 100)	8247 (7639; 8903)	224	100% (98.4; 100)	2633 (2299; 3014)
	Year 3 ⁽²⁾	449	82.0% (78.1; 85.4)	338 (268; 426)	150	30.0% (22.8; 38.0)	16.0 (10.9; 23.6)
	Year 5 ⁽²⁾	236	86.0% (80.9; 90.2)	437 (324; 588)	86	34.9% (24.9; 45.9)	19.7 (11.8; 32.9)
	Year 10 ⁽³⁾ (Pre-booster)	162	71.6% (64.0; 78.4)	146 (97.6; 217)	51	43.1% (29.3; 57.8)	16.4 (9.2; 29.4)
	(Post-booster) ^(3,4)	162	100% (97.7; 100)	11243 (9367; 13496)	51	100% (93.0; 100)	3674 (2354; 5734)
Y	Month 1 ⁽¹⁾	677	100% (99.5; 100)	14087 (13168; 15069)	224	100% (98.4; 100)	5066 (4463; 5751)
	Year 3 ⁽²⁾	449	93.1% (90.3; 95.3)	740 (620; 884)	150	58.0% (49.7; 66.0)	69.6 (44.6; 109)
	Year 5 ⁽²⁾	236	96.6% (93.4; 98.5)	1000 (824; 1214)	86	66.3% (55.3; 76.1)	125 (71.2; 219)
	Year 10 ⁽³⁾ (Pre-booster)	162	90.7% (85.2; 94.7)	447 (333; 599)	51	49.0% (34.8; 63.4)	32.9 (17.1; 63.3)
	(Post-booster) ^(3,4)	162	100% (97.7; 100)	7585 (6748; 8525)	51	98.0% (89.6; 100)	3296 (1999; 5434)

The analysis of immunogenicity was conducted on the ATP cohort for each time point.

(1) Study MenACWY-TT-036

(2) Study MenACWY-TT-043

(3) Study MenACWY-TT-101

(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

In Study MenACWY-TT-059, the hSBA persistence was evaluated up to 5 years after vaccination compared to MENACTRA in adolescents and adults 11-25 years of age initially vaccinated in Study MenACWY-TT-052 (Table 21). At 1, 3 and 5 years following the primary vaccination 64% / 60%, 58% / 43.2%, and 25% / 23% of the subjects were included in the evaluation for NIMENRIX / MENACTRA, respectively.

For all meningococcal groups, the persistence of the hSBA titres elicited by NIMENRIX was similar to or higher than those induced by MENACTRA.

Table 21 hSBA* titres following a single dose of NIMENRIX (or ACWY-DT) in adolescents and adults 11-25 years of age and persistence up to 5 years following vaccination (Studies MenACWY-TT-052/-059)

Meningococcal group	Timepoint	N	NIMENRIX %	N	Active Control (MENACTRA) %
hSBA-Men A	Month 1 ⁽¹⁾	356	82.0%	107	73.8%
	Year 1 ⁽²⁾	350	29.1%	111	31.5%
	Year 3 ⁽²⁾	316	37.3%	79	48.1%
	Year 5 ⁽²⁾	141	48.9%	45	44.4%
hSBA-Men C	Month 1 ⁽¹⁾	359	96.1%	113	99.1%
	Year 1 ⁽²⁾	336	94.9%	105	73.3%
	Year 3 ⁽²⁾	319	93.1%	81	81.5%
	Year 5 ⁽²⁾	140	92.9%	44	79.5%
hSBA-MenW-135	Month 1 ⁽¹⁾	334	91.0%	97	75.3%
	Year 1 ⁽²⁾	327	98.5%	108	75.9%
	Year 3 ⁽²⁾	323	95.4%	80	85.0%
	Year 5 ⁽²⁾	138	87.0%	44	84.1%
hSBA-Men Y	Month 1 ⁽¹⁾	364	95.1%	111	81.1%
	Year 1 ⁽²⁾	356	97.8%	112	86.6%
	Year 3 ⁽²⁾	321	96.0%	80	88.8%
	Year 5 ⁽²⁾	142	94.4%	44	90.9%

The analysis of immunogenicity was conducted on the ATP cohort for persistence adapted for each timepoint.

*hSBA analysis performed at GSK laboratories

(1) Study MenACWY-TT-052

(2) Study MenACWY-TT-059

Vaccine response defined as: post-vaccination antibody titre \geq 1:8

rSBA titres were determined over a period of 10 years in subjects initially vaccinated with one dose of NIMENRIX or ACWY-PS at 11 to 55 years of age in Study MenACWY-TT-015. Persistence of rSBA titres was evaluated in two extension studies: MenACWY-TT-020 (up to 5 years) and MenACWY-TT-099 (up to 10 years). Study MenACWY-TT-099 also evaluated the response to a single booster dose of NIMENRIX administered 10 years following the initial vaccination with NIMENRIX or ACWY-PS. Results are shown in Table 22.

Table 22: rSBA* titres following a single dose of NIMENRIX (or ACWY-PS) in adolescents and adults aged 11-55 years, persistence up to 10 years, and post-booster administered 10 years following initial vaccination (Studies MenACWY-TT-015/020/099)

Meningo-coccal group	Time point	NIMENRIX			ACWY-PS vaccine		
		N	≥1:8 (95% CI)	GMT (95% CI)	N	≥1:8 (95% CI)	GMT (95% CI)
A	Month 1 ⁽¹⁾	323	100% (98.9; 100)	4945 (4452, 5493)	112	100% (96.8, 100)	2190 (1858, 2582)
	Year 4 ⁽²⁾	43	95.3% (84.2; 99.4)	365 (226; 590)	17	76.5% (50.1; 93.2)	104 (31.0; 351)
	Year 5 ⁽²⁾	51	84.3% (71.4; 93.0)	190 (108; 335)	19	57.9% (33.5; 79.7)	37.0 (12.6; 109)
	Year 10 ⁽³⁾ (Pre-booster)	155	78.1% (70.7; 84.3)	154 (108; 219)	52	71.2% (56.9; 82.9)	75.1 (41.4; 136)
	(Post-booster) ^(3,4)	155	100% (97.6; 100)	4060 (3384; 4870)	52	100% (93.2; 100)	3585 (2751; 4672)
C	Month 1 ⁽¹⁾	341	99.7% (98.4; 100)	10074 (8700, 11665)	114	100% (96.8; 100)	6546 (5048; 8488)
	Year 4 ⁽²⁾	43	76.7% (61.4; 88.2)	126 (61.6; 258)	17	41.2% (18.4; 67.1)	16.7 (5.7; 48.7)
	Year 5 ⁽²⁾	51	72.5% (58.3; 84.1)	78.5 (41.8; 147)	18	38.9% (17.3; 64.3)	17.3 (6.0; 49.7)
	Year 10 ⁽³⁾ (Pre-booster)	154	90.9% (85.2; 94.9)	193 (141; 264)	52	88.5% (76.6; 95.6)	212 (110; 412)
	(Post-booster) ^(3,4)	155	100% (97.6; 100)	13824 (10840; 17629)	52	98.1% (89.7; 100)	3444 (1999; 5936)
W-135	Month 1 ⁽¹⁾	340	99.7% (98.4; 100)	8577 (7615; 9660)	114	100% (96.8; 100)	2970 (2439; 3615)
	Year 4 ⁽²⁾	43	90.7% (77.9; 97.4)	240 (128; 450)	17	17.6% (3.8; 43.4)	8.3 (3.6; 19.5)
	Year 5 ⁽²⁾	51	86.3% (73.7; 94.3)	282 (146; 543)	19	31.6% (12.6; 56.6)	15.4 (5.7; 41.9)
	Year 10 ⁽³⁾ (Pre-booster)	154	71.4% (63.6; 78.4)	166 (107; 258)	52	21.2% (11.1; 34.7)	10.9 (6.1; 19.3)
	(Post-booster) ^(3,4)	155	100% (97.6; 100)	23431 (17351; 31641)	52	98.1% (89.7; 100)	5793 (3586; 9357)
Y	Month 1 ⁽¹⁾	340	100% (98.9; 100)	10315 (9317; 11420)	114	100% (96.8; 100)	4574 (3864; 5414)
	Year 4 ⁽²⁾	43	86.0% (72.1; 94.7)	443 (230; 853)	17	47.1% (23.0; 72.2)	30.7 (9.0; 105)
	Year 5 ⁽²⁾	51	92.2% (81.1; 97.8)	770 (439; 1351)	19	63.2% (38.4; 83.7)	74.1 (21.9; 250)
	Year 10 ⁽³⁾ (Pre-booster)	154	86.4% (79.9; 91.4)	364 (255; 519)	52	61.5% (47.0; 74.7)	56.0 (28.8; 109)
	(Post-booster) ^(3,4)	155	100% (97.6; 100)	8958 (7602; 10558)	52	100% (93.2; 100)	5138 (3528; 7482)

The analysis of immunogenicity was conducted on the ATP cohorts for 1 month and 5 years post vaccination and the booster ATP cohort.

(1) Study MenACWY-TT-015

(2) Study MenACWY-TT-020

(3) Study MenACWY-TT-099

(4) Blood sampling was performed 1 month after a booster dose at Year 10.

*rSBA analysis performed at GSK laboratories for 1 month post primary vaccination samples and at PHE laboratories in UK for the subsequent sampling time points.

Immunogenicity in adults aged > 55 years

A descriptive study (MenACWY-TT-085) was conducted to evaluate the immunogenicity of NIMENRIX compared to ACWY-PS vaccine, in terms of meningococcal groups A, C, W-135 and Y bactericidal vaccine response¹ 1 month after the vaccination. A single dose of vaccine was administered to 369 Lebanese adults 56 years of age and older (including 274 and 95 subjects in the treatment and control groups, respectively). The analysis of immunogenicity was evaluated based on 260 subjects included in the ATP cohort for immunogenicity (194 and 66 subjects in the treatment and control groups, respectively). The vaccine response ranged from 76.6% (rSBA-MenA) to 81.9% (rSBA-MenY) in the NIMENRIX group and from 84.8% (rSBA-MenC) to 91.7% (rSBA-MenA) in the ACWY-PS group. Of the 194 subjects in the treatment group, the percentage of subjects with rSBA titres $\geq 1:128$ before vaccination ranged from 45% (MenC) to 62% (MenY). Overall, at 1 month post-vaccination the percentage of vaccinees with rSBA titres $\geq 1:128$ ranged from 93% (MenC) to 97% (MenY). The supplementary analysis showed that in the subgroup aged >65 years the percentage of vaccinees with rSBA titres $\geq 1:128$ at 1 month post-vaccination ranged from 90% (MenA) to 97% (MenY).

Booster response for subjects previously vaccinated with a conjugate meningococcal vaccine against *Neisseria meningitidis*

NIMENRIX booster vaccination in subjects previously primed with a monovalent (MenC-CRM) or a quadrivalent conjugate meningococcal vaccine (MenACWY-TT) was studied in subjects from 12 months of age onwards who received a booster vaccination. Robust anamnestic responses to the antigen(s) in the priming vaccine were observed (see Tables 12, 13, 17, 20, and 22).

Response to NIMENRIX in subjects previously vaccinated with a plain polysaccharide meningococcal vaccine

In Study MenACWY-TT-021 conducted in subjects aged 4.5-34 years, the immunogenicity of NIMENRIX administered between 30 and 42 months after vaccination with an ACWY-PS vaccine was compared to the immunogenicity of NIMENRIX administered to age-matched subjects who had not been vaccinated with any meningococcal vaccine in the preceding 10 years. An immune response (rSBA titre $\geq 1:8$) was observed against all groups (A, C, W-135, Y) in all subjects regardless of the meningococcal vaccine history. The rSBA GMTs were significantly lower in the subjects who had received a dose of ACWY-PS vaccine 30-42 months prior to NIMENRIX. However, rSBA GMTs did increase post-vaccination for all four meningococcal groups, ranging from 3.9- to 30.1-fold in the ACWY-PS group and from 11.8- to 246.0-fold in the no ACWY-PS group. At least 97.0% of the subjects in the ACWY-PS group demonstrated post-vaccination rSBA titres $\geq 1:128$ for all four meningococcal groups.

^aVaccine response to meningococcal antigens (MenA, MenC, MenW-135 and MenY) at one month post vaccination, defined as:

- for initially seronegative subjects (rSBA titre less than 1:8), post vaccination rSBA titre $\geq 1:32$
- for initially seropositive subjects with rSBA titre between 1:8 and 1:128, at least four-fold increase in rSBA titre from pre to post vaccination
- for initially seropositive subjects with rSBA titres $\geq 1:128$, at least two-fold increase in rSBA titre from pre to post vaccination

Immunogenicity in children (2-17 years) with anatomic or functional asplenia

Study MenACWY-TT-084 evaluated the immune responses of two doses of NIMENRIX given two months apart in 43 subjects aged 2-17 years with anatomic or functional asplenia, and 43 age-matched subjects with normal splenic function. One month after the first vaccine dose, vaccine response rates (rSBA titre $\geq 1:32$ or a ≥ 4 -fold increase in rSBA titre from baseline) for groups A, C, W-135, and Y, respectively, were 100%, 92.5%, 100% and 97.5% in the at-risk group, and were 97.5%, 97.5%, 97.5%, and 100% in the healthy subjects. After the second dose, vaccine response rates were 100% for each of the 4 meningococcal groups, in both at-risk and healthy subjects.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Non-clinical data reveal no special hazard for humans based on local tolerance, acute toxicity, repeated dose toxicity, developmental/reproductive toxicity and fertility studies.

Table 23 Nonclinical toxicology studies

Study type and species	Route and dosage regimen	Results
Local tolerance and acute toxicity New Zealand White rabbit	One intramuscular injection; full human dose	No distinct treatment-related changes in general and local clinical signs and body weight. No macroscopic abnormalities seen at injection site. A slight mononuclear type inflammation was observed microscopically at the injection sites of both the saline control and MenACWY-TT groups.
Repeated dose toxicity New Zealand White rabbit	Five repeated intramuscular injections two weeks apart; full human dose per injection	No treatment-related changes observed in general and in local clinical signs, ophthalmoscopy, rectal body temperature, haematology, clinical chemistry or organ weights. Very slight to slight inflammation in the injected muscles which diminished distinctly over time with a clear recovery process observed 28 days after the last dose. No adverse vaccine formulation-related histopathological changes were observed any other tissues or organs.
Reproductive and developmental toxicity Wistar rat	Intramuscular injection 42 and 28 days before mating and on gestation days 6, 8, 11 and 15; 2/5 of the full human dose per injection (200 μ L)	No treatment-related effects on maternal toxicity, prenatal development (including external, visceral and skeletal abnormalities), or postnatal development

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

NIMENRIX®

Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine Powder and diluent for solution for injection

Read this carefully before you/your child receive **NIMENRIX**. This leaflet is a summary and will not tell you everything about this vaccine. Talk to your healthcare professional about your/your child's medical condition and treatment and ask if there is any new information about **NIMENRIX**.

What is NIMENRIX used for?

- NIMENRIX is a vaccine that may be given to infants from the age of 6 weeks, children, adolescents and adults up to 55 years old to prevent illness caused by *Neisseria meningitidis* types A, C, W-135 and Y bacteria (germs).

Neisseria meningitidis types A, C, W-135 and Y bacteria most often cause meningitis (infection of the tissue lining the brain) and septicemia (infection of the blood). These diseases can be highly infectious and are sometimes fatal.

As with all vaccines, NIMENRIX may not fully protect all people who are vaccinated.

NIMENRIX will only protect against infections caused by groups of *Neisseria meningitidis* for which the vaccine has been developed.

How does NIMENRIX work?

The vaccine works by causing the body to produce its own protection (antibodies) against these bacteria. The vaccine cannot cause these diseases.

What are the ingredients in NIMENRIX?

Medicinal ingredients: Each 0.5 mL dose contains 5 micrograms of each of the *Neisseria meningitidis* capsular polysaccharides A, C, W-135 and Y each coupled to tetanus toxoid as a carrier protein.

Non-medicinal ingredients:

- Powder: sucrose, trometamol
- Diluent: sodium chloride, water for injections

NIMENRIX comes in the following dosage forms:

Powder (in a single dose vial) and diluent for solution for injection (in a pre-filled syringe).

Do not use NIMENRIX if:

- You/your child have previously had any allergic reaction to NIMENRIX, or to any ingredient contained in NIMENRIX. Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you/your child receive NIMENRIX. Talk about any health conditions or problems you/your child may have, including if:

- you or your child have/has a severe infection with a high temperature. In these cases, the vaccination will be postponed until recovery. A minor infection such as a cold should not be a problem, but talk to your health professional first.
- you or your child have/has a bleeding problem or bruise(s) easily.
- you or your child have/has a weakened immune system, for example due to HIV infection or complement deficiencies or due to medicines that suppress the immune system (for example, eculizumab). You or your child may not get the full benefit from NIMENRIX, or may remain at increased risk for disease caused by meningococcal groups A, C, W-135 and Y bacteria even if you develop antibodies following vaccination with NIMENRIX.
- you are pregnant or breastfeeding.

Other warnings you should know about:

Fainting can occur following, or even before, any needle injection, therefore tell your health professional if you/your child fainted with a previous injection.

Tell your healthcare professional about all the medicines you/your child take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Please tell your health professional if you/your child have/has recently received any other vaccine.

NIMENRIX can be given at the same time as other vaccines such as hepatitis A and hepatitis B vaccines, measles-mumps-rubella vaccine, measles-mumps-rubella-varicella vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.

In the first two years of life, NIMENRIX can also be given at the same time or at least one month before a combined diphtheria-tetanus-acellular pertussis vaccine, including combination diphtheria-tetanus-acellular pertussis vaccine with hepatitis B, inactivated poliovirus or *Haemophilus influenzae* type b, such as DTaP/IPV/Hib/HepB vaccine, and 13-valent pneumococcal conjugate vaccine.

In individuals aged 9 to 25 years, NIMENRIX can be given at the same time with human papillomavirus vaccine [Types 16, 18] and a combined diphtheria (reduced antigen content), tetanus and acellular pertussis vaccine.

A different injection site will be used for each vaccine.

The following may interact with NIMENRIX:

NIMENRIX may not work as well if you/your child are/is taking medicines that reduce the effectiveness of your/your child's immune system to fight infection.

How NIMENRIX is given:

Usual dose:

Your health professional will give NIMENRIX as an injection into the muscle, in the upper arm or thigh.

NIMENRIX is given as an injection of 0.5 mL.

Primary immunization

Infants from 6 weeks to less than 6 months of age

Your child will receive two injections given 2 months apart at e.g., 2 and 4 months of age (the first injection may be given from the age of 6 weeks).

From 6 months to 55 years of age

Infants 6 months and older, children, adolescents and adults should receive one dose of vaccine.

Booster doses

Infants from 6 weeks to less than 12 months of age

One booster dose at 12 months of age, at least 2 months after the last dose of NIMENRIX.

Previously vaccinated individuals 12 months of age and older

Please tell your doctor if you or your child have received a previous dose of NIMENRIX or another meningococcal vaccine.

Your doctor will tell you if and when you need an additional dose of NIMENRIX, especially if you or your child:

- received your first dose at age 6-14 months and could be at particular risk of infection caused by *Neisseria meningitidis* types W-135 and/or Y
- received your dose more than approximately one year ago and could be at risk of infection caused by *Neisseria meningitidis* type A
- received your first dose at age 12-23 months and could be at particular risk of infection caused by *Neisseria meningitidis* types A, C, W-135 and Y

You will be informed when you or your child should come back for the next injection.

Overdose:

If you think you, or a person you are caring for, have received too much NIMENRIX, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

If you or your child misses a scheduled injection, it is important that you make another appointment.

Make sure that you or your child finishes the complete vaccination course.

What are possible side effects from using NIMENRIX?

A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. The risk of NIMENRIX causing serious harm is extremely small. The small risks associated with NIMENRIX are much less than the risk associated with getting the disease.

In infants, adolescents and adults, very common side effects (in more than 1 in 10 doses of the vaccine) after having NIMENRIX are loss of appetite, irritability, drowsiness, headache, fever, swelling, pain and redness at the injection site and fatigue.

Common side effects (in more than 1 in 100 and up to 1 in 10 doses of the vaccine) after having NIMENRIX are gastrointestinal symptoms including diarrhea, vomiting and nausea, injection site hematoma, and rash (infants).

Uncommon side effects (in more than 1 in 1,000 and up to 1 in 100 doses of the vaccine) after having NIMENRIX are insomnia, crying, dizziness, decreased feeling or sensitivity especially in the skin, itching, rash, hives, aching muscles, pain in extremity (pain in the limb), generally feeling unwell, and injection site reaction (such as a hard lump at the injection site, itching warmth and loss of feeling).

The most common side effects reported during clinical trials usually lasted only one to two days and were not usually severe.

The following additional side effect has been reported during marketed use and so the frequency cannot be estimated from the available data: large swelling of the vaccinated limb associated with redness.

Do not be alarmed by this list of possible side effects. It is possible that you or your child will have no side effects from vaccination.

These are not all the possible side effects you may have when taking NIMENRIX. If you experience any side effects not listed here, tell your health professional.

Tell your health professional as soon as possible if you or your child does not feel well after receiving NIMENRIX.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your health professional.

Reporting Suspected Side Effects for Vaccines

For the general public: Should you experience a side effect following immunization, please report it to your healthcare professional.

Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada, Health Canada and Pfizer Canada ULC cannot provide medical advice.

For healthcare professionals: If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (<http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng.php>) and send it to your local Health Unit.

Storage:

Keep out of reach and sight of children. Store in a refrigerator (2°C – 8°C). Do not freeze. Store in the original package in order to protect from light.

If you want more information about NIMENRIX:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website <https://www.pfizer.ca>, or by calling 1-800-463-6001.

This leaflet was prepared by Pfizer Canada ULC.

Last Revised: